Gefitinib (ZD1839)

Name: Gefitinib (ZD1839)
Brand: Selleck Chemicals
SKU: S1025
Rating: 5 (514 reviews)

For research use only.

Catalog No.S1025 Synonyms: Iressa

514 publications

CAS No. 184475-35-2

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Selleck's Gefitinib (ZD1839) has been cited by 514 publications

Nat Cell Biol, 2021, 23(4):377-390

PubMed: 33795873 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):782-792e7

PubMed: 32348727 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(1):104-122e12

PubMed: 31935369 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cell Stem Cell, 2019, 25(1):69-86

PubMed: 31080136 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Cancer Cell, 2018, 34(3):427-438

PubMed: 30205045 ( click the link to review the publication )

Nature, 2017, 547(7664):453-457

PubMed: 28678785 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Nat Med, 2016, 22(3):262-9

PubMed: 26828195 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2015, 5(9):960-971

PubMed: 26036643 ( click the link to review the publication )

Nature, 2014, 3;508(7494):118-22.

PubMed: 24670642 ( click the link to review the publication )

Nat Med, 2013, 19(11):1469-1472

PubMed: 24162815 ( click the link to review the publication )

Nature, 2012, 26;483(7387):100-3.

PubMed: 22281684 ( click the link to review the publication )

Cell, 2012, 21;151(5):937-50.

PubMed: 23178117 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Nat Commun, 2021, 12(1):2624

PubMed: 33976143 ( click the link to review the publication )

Clin Cancer Res, 2021, clincanres.0714.2021

PubMed: 34168046 ( click the link to review the publication )

Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

Theranostics, 2021, 11(6):2594-2611

PubMed: 33456562 ( click the link to review the publication )
Mol Cancer, 2021, 20(1):17

PubMed: 33461557 ( click the link to review the publication )

Cancers (Basel), 2021, 13(2)E272

PubMed: 33450879 ( click the link to review the publication )

Cancers (Basel), 2021, 13(6)1198

PubMed: 33801941 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009221

PubMed: 33471869 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):83

PubMed: 33446634 ( click the link to review the publication )

Cell Death Dis, 2021, 12(6):561

PubMed: 34059647 ( click the link to review the publication )

Br J Cancer, 2021, 10.1038/s41416-021-01340-x

PubMed: 34088989 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13046

PubMed: 34165921 ( click the link to review the publication )

Pharmacol Res, 2021, 170:105701

PubMed: 34087353 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(4):1873-1888

PubMed: 34012799 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(3):1277-1291

PubMed: 33889509 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2021, 1868(6):119016

PubMed: 33744274 ( click the link to review the publication )

Front Oncol, 2021, 11:665045

PubMed: 34168988 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(10)5306

PubMed: 34069970 ( click the link to review the publication )

Sci Rep, 2021, 11(1):7259

PubMed: 33790333 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Proteomics, 2021, 10.1002/pmic.202000251

PubMed: 34151541 ( click the link to review the publication )

Environ Toxicol, 2021, 10.1002/tox.23125

PubMed: 33734566 ( click the link to review the publication )

Jpn J Clin Oncol, 2021, hyab048

PubMed: 33829270 ( click the link to review the publication )

Oncol Lett, 2021, 21(5):418

PubMed: 33841579 ( click the link to review the publication )

Transl Lung Cancer Res, 2021, 10(1):128-142

PubMed: 33569299 ( click the link to review the publication )

Sci Total Environ, 2021, 775:145814

PubMed: 33621883 ( click the link to review the publication )

Pharmaceutics, 2021, 13(5)630

PubMed: 33925114 ( click the link to review the publication )
FASEB J, 2021, 35(3):e21393

PubMed: 33570794 ( click the link to review the publication )

Toxicol Lett, 2021, S0378-4274(21)00043-6

PubMed: 33571620 ( click the link to review the publication )

Acta Neuropathol, 2020, 17

PubMed: 32303840 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 21;11(1):1923

PubMed: 32317663 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4607

PubMed: 32929081 ( click the link to review the publication )

Nat Commun, 2020, 25;11(1):1556

PubMed: 32214092 ( click the link to review the publication )

Sci Adv, 2020, 6(11):eaax2271

PubMed: 32195335 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.3555.2020

PubMed: 33355298 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432

PubMed: 32034078 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Mol Syst Biol, 2020, 16(2):e8664

PubMed: 32073727 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Aging Cell, 2020, 22:e13145

PubMed: 32323422 ( click the link to review the publication )

Elife, 2020, 9e60541

PubMed: 32940599 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01465-y

PubMed: 32978523 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 475:109-118

PubMed: 32004572 ( click the link to review the publication )

Sci Signal, 2020, 3;13(621) pii: eaax2364

PubMed: 32127496 ( click the link to review the publication )

Cancers (Basel), 2020, 12(12)E3761

PubMed: 33327495 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )
Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):768

PubMed: 32943616 ( click the link to review the publication )

Cell Death Dis, 2020, 11(2):143

PubMed: 32081857 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0952-1

PubMed: 32572172 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):214

PubMed: 33033232 ( click the link to review the publication )

Cancer Discov, 2020, 15 pii: CD-20-0116

PubMed: 32414908 ( click the link to review the publication )

Front Immunol, 2020, 10:3135

PubMed: 32082304 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371577 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 31 pii: mcp

PubMed: 32234966 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

J Cancer, 2020, 6;11(13):3762-3770

PubMed: 32328181 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(5):1652-1662

PubMed: 32133706 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3813-3823

PubMed: 32735723 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(12):4251-4265

PubMed: 33414998 ( click the link to review the publication )

Oncogenesis, 2020, 9(10):87

PubMed: 33012785 ( click the link to review the publication )

Biomolecules, 2020, 10(1)

PubMed: 31947839 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Mol Cancer Res, 2020, 25

PubMed: 32098826 ( click the link to review the publication )

Front Oncol, 2020, 9:1503

PubMed: 31993373 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:554704

PubMed: 33330026 ( click the link to review the publication )

Cell Microbiol, 2020, e13240

PubMed: 32584493 ( click the link to review the publication )
J Cell Mol Med, 2020, 24(10):5578-5592

PubMed: 32248643 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(10):5811-5816

PubMed: 32281297 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(20)E7770

PubMed: 33092268 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Biomed Pharmacother, 2020, 16;127:110225

PubMed: 32428834 ( click the link to review the publication )

Invest New Drugs, 2020, 38(4):1003-1011

PubMed: 31612426 ( click the link to review the publication )

Am J Transl Res, 2020, 12(11):7377-7385

PubMed: 33312374 ( click the link to review the publication )

Infect Immun, 2020, 88(4)e00819-19

PubMed: 31964750 ( click the link to review the publication )

Oncol Rep, 2020, 45(2):459-468

PubMed: 33416163 ( click the link to review the publication )

Eur J Pharmacol, 2020, 5;874:172961

PubMed: 32044322 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Thorac Cancer, 2020, 5

PubMed: 32368855 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13533

PubMed: 32558328 ( click the link to review the publication )

Thorac Cancer, 2020, 10.1111/1759-7714.13670

PubMed: 32956565 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Med Invest, 2020, 67(3.4):343-350

PubMed: 33148913 ( click the link to review the publication )

J Thorac Dis, 2020, 12(3):712-723

PubMed: 32274137 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020,

PubMed: 32843430 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):670

PubMed: 32820157 ( click the link to review the publication )
Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Front Oncol, 2020, 10:603883

PubMed: 33585221 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):1189

PubMed: 33276757 ( click the link to review the publication )

Exp Mol Med, 2020, 10.1038/s12276-020-0474-1

PubMed: 32728068 ( click the link to review the publication )

Cells, 2020, 9(8):E1830

PubMed: 32756527 ( click the link to review the publication )

Cytometry A, 2020, 97(1):70-77

PubMed: 31411813 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Fundam Clin Pharmacol, 2020, 10.1111/fcp.12641

PubMed: 33336420 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107994

PubMed: 32755586 ( click the link to review the publication )

Viruses, 2020, 12(11)E1294

PubMed: 33198108 ( click the link to review the publication )

Exp Cell Res, 2020, 390(2):111950

PubMed: 32188578 ( click the link to review the publication )

Cell Syst, 2020, S2405-4712(20)30247-7

PubMed: 32726596 ( click the link to review the publication )

Rapid Commun Mass Spectrom, 2020, 10.1002/rcm.8955

PubMed: 32990383 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Cancer Treat Res Commun, 2020, 25:100229

PubMed: 33152554 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 73(1):166-182

PubMed: 30609389 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.30780

PubMed: 31127639 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2919

PubMed: 31266962 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1660545

PubMed: 31462148 ( click the link to review the publication )

EMBO J, 2019, 38(4)

PubMed: 30643021 ( click the link to review the publication )
Cancer Res, 2019, 79(4):819-829

PubMed: 30573522 ( click the link to review the publication )

J Am Soc Nephrol, 2019, 30(8):1454-1470

PubMed: 31253651 ( click the link to review the publication )

Matrix Biol, 2019, 10.1016/j.matbio.2019.07.006

PubMed: 31323325 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Mol Cancer, 2019,

PubMed: 31747941 ( click the link to review the publication )

Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Int J Cancer, 2019, 145(5):1432-1444

PubMed: 30784054 ( click the link to review the publication )

Oncogene, 2019, 38(14):2464-2481

PubMed: 30532069 ( click the link to review the publication )

Oncogene, 2019, 38(11):1936-1950

PubMed: 30390071 ( click the link to review the publication )

Oncogene, 2019, 38(37):6399-6413

PubMed: 31324888 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):46

PubMed: 30709379 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):96

PubMed: 30791926 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31635301 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):283

PubMed: 30911072 ( click the link to review the publication )

Signal Transduct Target Ther, 2019,

PubMed: 32651361 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:25

PubMed: 31637005 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cells, 2019, 8(12)E1495

PubMed: 31771093 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(5):805-819

PubMed: 31670920 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0181

PubMed: 31501278 ( click the link to review the publication )
Cell Prolif, 2019, 52(6):e12680

PubMed: 31454111 ( click the link to review the publication )

Cell Prolif, 2019,

PubMed: 31094020 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Biomolecules, 2019, 9(10)E638

PubMed: 31652643 ( click the link to review the publication )

Lung Cancer, 2019, 137:85-93

PubMed: 31563735 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(3):606-617

PubMed: 31565489 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

DNA Repair (Amst), 2019, 78:37-44

PubMed: 30954901 ( click the link to review the publication )

Front Oncol, 2019, 9:1167

PubMed: 31750252 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:117

PubMed: 31073278 ( click the link to review the publication )

Mol Carcinog, 2019, 10.1002/mc.23139

PubMed: 31777985 ( click the link to review the publication )

Mol Carcinog, 2019,

PubMed: 30811684 ( click the link to review the publication )

Front Pharmacol, 2019, 10:1116

PubMed: 31649529 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Respir Res, 2019, 20(1):164

PubMed: 31331328 ( click the link to review the publication )

Biomed Pharmacother, 2019, 118:109169

PubMed: 31310954 ( click the link to review the publication )

J Proteomics, 2019, 195:114-124

PubMed: 30660770 ( click the link to review the publication )
Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

Mediators Inflamm, 2019,

PubMed: 32082070 ( click the link to review the publication )

Life Sci, 2019, 224:23-32

PubMed: 30902544 ( click the link to review the publication )

J Drug Target, 2019, 27(4):451-459

PubMed: 30381967 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 106:96-106

PubMed: 30471423 ( click the link to review the publication )

Molecules, 2019, 24(3)

PubMed: 30754629 ( click the link to review the publication )

Transl Oncol, 2019, 12(11):1516-1524

PubMed: 31450127 ( click the link to review the publication )

Eur J Pharmacol, 2019, 855:10-19

PubMed: 31028739 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Eur J Pharmacol, 2019, 856:172409

PubMed: 31132355 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:6033-6043

PubMed: 31440060 ( click the link to review the publication )

Biomed Res Int, 2019, 2019:3129748

PubMed: 31346515 ( click the link to review the publication )

J Cancer Prev, 2019, 24(4):217-223

PubMed: 31950021 ( click the link to review the publication )

Mol Med Rep, 2019,

PubMed: 31638204 ( click the link to review the publication )

Oncol Lett, 2019, 18(5):5621-5627

PubMed: 31620204 ( click the link to review the publication )

Oncol Lett, 2019, 18(1):368-374

PubMed: 31289508 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

Exp Ther Med, 2019, 18(5):3793-3800

PubMed: 31611933 ( click the link to review the publication )

Exp Ther Med, 2019, 17(1):953-959

PubMed: 30651886 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30975694 ( click the link to review the publication )
Zhongguo Fei Ai Za Zhi, 2019, 22(5):255-263

PubMed: 31109434 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Nat Microbiol, 2019, 4(2):216-225

PubMed: 30420785 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Oncotarget, 2019, 10(26):2546-2560

PubMed: 31069016 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4728

PubMed: 30413706 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(3)

PubMed: 29449326 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3097-3107

PubMed: 29506987 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3928-3940

PubMed: 29685880 ( click the link to review the publication )

EMBO Rep, 2018,

PubMed: 29335246 ( click the link to review the publication )

Theranostics, 2018, 8(5):1256-1269

PubMed: 29507618 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):109

PubMed: 30157900 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Oncogene, 2018, 37(9):1251-1262

PubMed: 29242605 ( click the link to review the publication )

Cancer Lett, 2018, 424:84-96

PubMed: 29524558 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 3;37(1):131

PubMed: 29970127 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Basic Res Cardiol, 2018, 113(2):12

PubMed: 29349588 ( click the link to review the publication )
FASEB J, 2018, 10.1096/fj.201800011R

PubMed: 29812969 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e435

PubMed: 29371698 ( click the link to review the publication )

Exp Mol Med, 2018, 50(4):52

PubMed: 29700289 ( click the link to review the publication )

Cell Physiol Biochem, 2018,

PubMed: 29961070 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 51(1):337-355

PubMed: 30453282 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Cell Commun Signal, 2018, 16(1):77

PubMed: 30409180 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):883-895

PubMed: 29633504 ( click the link to review the publication )

Mol Oncol, 2018, 12(2):224-238

PubMed: 29193645 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(10):1892-1908

PubMed: 29970458 ( click the link to review the publication )

Eur J Med Chem, 2018, 144:330-348

PubMed: 29275232 ( click the link to review the publication )

Cancer Sci, 2018, 109(6):1775-1786

PubMed: 29624806 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(10):1458-1469

PubMed: 29934325 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Sci, 2018,

PubMed: 29487179 ( click the link to review the publication )

Antiviral Res, 2018, 150:20-29

PubMed: 29224735 ( click the link to review the publication )

Biochem Pharmacol, 2018, 152:327-337

PubMed: 29660315 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )
Respir Res, 2018, 19(1):96

PubMed: 29784046 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:6695-6703

PubMed: 30584364 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):50

PubMed: 30053908 ( click the link to review the publication )

Phytomedicine, 2018, 39:33-41

PubMed: 29433681 ( click the link to review the publication )

Int J Oncol, 2018, 52(6):2143-2154

PubMed: 29620166 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(10):921-933

PubMed: 29856687 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2171-2182

PubMed: 30106444 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):1937-1946

PubMed: 30106446 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):775-782

PubMed: 29901173 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):1046-1054

PubMed: 29917169 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8455-8463

PubMed: 30555238 ( click the link to review the publication )

J Gen Virol, 2018,

PubMed: 29624161 ( click the link to review the publication )

J Ovarian Res, 2018, 11(1):12

PubMed: 29402301 ( click the link to review the publication )

Cell Biol Int, 2018, 42(10):1311-1320

PubMed: 29907991 ( click the link to review the publication )

Mol Med Rep, 2018, 18(4):3882-3890

PubMed: 30106133 ( click the link to review the publication )

Oncol Lett, 2018, 15(3):2829-2838

PubMed: 29467862 ( click the link to review the publication )

Cell Mol Biol (Noisy-le-grand), 2018, 64(4):6-10

PubMed: 29631678 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(26):18254-18268

PubMed: 29719603 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29416603 ( click the link to review the publication )
Proc Natl Acad Sci U S A, 2018, 115(42):E9869-E9878

PubMed: 30275324 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 1;8(1):1232

PubMed: 29089541 ( click the link to review the publication )

Autophagy, 2017, 13(7):1093-1112

PubMed: 28513279 ( click the link to review the publication )

Neuro-oncology, 2017,

PubMed: 28575494 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(15):E3129-E3138

PubMed: 28351972 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Genes Dev, 2017, 31(17):1754-1769

PubMed: 28982759 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3551-3563

PubMed: 28428274 ( click the link to review the publication )

Cell Rep, 2017, 21(11):3298-3309

PubMed: 29241554 ( click the link to review the publication )

Mol Cancer, 2017, 16(1):34

PubMed: 28158983 ( click the link to review the publication )

Elife, 2017, 6e26733

PubMed: 28737489 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Oncogene, 2017, 36(8):1102-1111

PubMed: 27524413 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Oncogene, 2017, 36(6):731-745

PubMed: 27477696 ( click the link to review the publication )

J Med Chem, 2017, 60(17):7447-7458

PubMed: 28787156 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

ACS Infect Dis, 2017, 3(8):564-574

PubMed: 28537707 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1368-1377

PubMed: 28445002 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28684780 ( click the link to review the publication )
Sci Rep, 2017,

PubMed: 28939861 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(11):1501-1511

PubMed: 29022575 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Eur J Pharmacol, 2017, 821:21-28

PubMed: 29277715 ( click the link to review the publication )

Oncol Rep, 2017, 37(2):1212-1218

PubMed: 27959426 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 493(1):213-219

PubMed: 28899783 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 482(4):1334-1340

PubMed: 27939888 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Oncol Lett, 2017,

PubMed: 28927099 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(40):69185-69197

PubMed: 28978189 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22325-22343

PubMed: 28423611 ( click the link to review the publication )

Oncotarget, 2017, 8(54):92240-92253

PubMed: 29190911 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423644 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(70):115620-115631

PubMed: 29383186 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28427242 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )
Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(9):3296-312

PubMed: 27482886 ( click the link to review the publication )

Nat Commun, 2016, 7:12231

PubMed: 27456471 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

EMBO Rep, 2016, 17(5):724-38

PubMed: 27013495 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26640141 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

Acta Neuropathol Commun, 2016, 4(1):96

PubMed: 27586084 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27678331 ( click the link to review the publication )

Oral Oncol, 2016, 59:12-19

PubMed: 27424178 ( click the link to review the publication )

Oral Oncol, 2016, 56:62-70

PubMed: 27086488 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 10.1016/j.bbagen.2016.05.011

PubMed: 27180173 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Sci Rep, 2016, 6:32258

PubMed: 27558531 ( click the link to review the publication )

Clin Lung Cancer, 2016, 17(4):263-270

PubMed: 26707383 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Int J Oncol, 2016, 49(4):1427-36

PubMed: 27498706 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

Oncol Rep, 2016, 36(2):729-36

PubMed: 27373987 ( click the link to review the publication )
Neurosurg Focus, 2016, 41(6):E14

PubMed: 27903123 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(9):e0163149

PubMed: 27643613 ( click the link to review the publication )

Anal Biochem, 2016,

PubMed: 27059751 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34395-419

PubMed: 27284014 ( click the link to review the publication )

Oncotarget, 2016, 7(51):84951-84964

PubMed: 27825114 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(31):50258-50276

PubMed: 27384680 ( click the link to review the publication )

Oncotarget, 2016, 7(19):27959-74

PubMed: 27058897 ( click the link to review the publication )

Tumour Biol, 2016,

PubMed: 26286833 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27556697 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52392-52403

PubMed: 27447558 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.16

PubMed: 25656847 ( click the link to review the publication )

Nat Commun, 2015, 6:6377

PubMed: 25758528 ( click the link to review the publication )

Nat Commun, 2015, 6:6240

PubMed: 25670642 ( click the link to review the publication )

J Thorac Oncol, 2015, 10.1097/JTO.0000000000000500

PubMed: 25658629 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

EMBO Rep, 2015,

PubMed: 26341626 ( click the link to review the publication )

Cell Rep, 2015, 10.1016/j.celrep.2015.04.049

PubMed: 26027934 ( click the link to review the publication )
Int J Cancer, 2015, 137(12):2947-58

PubMed: 26089022 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25746002 ( click the link to review the publication )

Cancer Lett, 2015, 369(1):103-11

PubMed: 26297988 ( click the link to review the publication )

Cell Death Dis, 2015,

PubMed: 26469972 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(10-:2238-48

PubMed: 26208525 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 10.1074/mcp.M115.049783 mcp.M115.049783.

PubMed: 25953087 ( click the link to review the publication )

Lung Cancer, 2015, 88(1):16-23

PubMed: 25704955 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26268703 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26639561 ( click the link to review the publication )

J Biol Chem, 2015, 290(41):24784-92

PubMed: 26304118 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Breast Cancer Res Treat, 2015, 154(2):225-37

PubMed: 26487496 ( click the link to review the publication )

Int J Oncol, 2015, 46(3):1214-24

PubMed: 25530180 ( click the link to review the publication )

Oncol Rep, 2015, 33(4):1860-6

PubMed: 25634113 ( click the link to review the publication )

Oncol Rep, 2015, 34(3):1613-9

PubMed: 26166014 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

PLoS ONE, 2015,

PubMed: 25969993 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144368

PubMed: 26656173 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )
Mol Med Rep, 2015,

PubMed: 25483995 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2795-803

PubMed: 25964559 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23857-73

PubMed: 26160843 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2015, 10.1016/j.ijrobp.2015.01.026

PubMed: 25823448 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncoscience, 2015, 2(4):419-427

PubMed: 26097875 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015, 6(12):10146-60

PubMed: 25760142 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Sci Transl Med, 2014, 6(219):219ra9

PubMed: 24431113 ( click the link to review the publication )

Mol Cell, 2014, 55(6):904-15

PubMed: 25219500 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Mol Cancer, 2014, 13:240

PubMed: 25342548 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Int J Cancer, 2014, 134(11):2560-71

PubMed: 24374738 ( click the link to review the publication )

Oncogene, 2014, 33(19):2495-503

PubMed: 23728339 ( click the link to review the publication )

Oncogene, 2014, 33(35):4385-95

PubMed: 24096476 ( click the link to review the publication )

MBio, 2014, 5(4):e01340-14

PubMed: 25096879 ( click the link to review the publication )

Cancer Lett, 2014, 342(1):82-91

PubMed: 24001610 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Mol Oncol, 2014, 9(1):260-9

PubMed: 25226813 ( click the link to review the publication )
Cell Oncol , 2014, 37(5):377-86

PubMed: 25228008 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):141-6

PubMed: 24957682 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 16):3555-67

PubMed: 24951116 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

Int J Biol Sci, 2014,

PubMed: 25013379 ( click the link to review the publication )

Colloids and Surfaces B: Biointerfaces, 2014, 123:61-7

PubMed: 25216919 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(3):318-22

PubMed: 24335466 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Int J Oncol, 2014, 45(1):393-400

PubMed: 24819550 ( click the link to review the publication )

Prostate, 2014, 74(5):528-36

PubMed: 24435707 ( click the link to review the publication )

Cell Cycle, 2014,

PubMed: 25426675 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3808-17

PubMed: ( click the link to review the publication )

Am J Physiol Renal Physiol, 2014, 307(4):F435-44

PubMed: 24990892 ( click the link to review the publication )

Oncol Rep, 2014, 32(5):2230-6

PubMed: 25175149 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 74(3):511-20

PubMed: 25038613 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115144

PubMed: 25502225 ( click the link to review the publication )

PLoS One, 2014, 9(4):e93651

PubMed: 24695557 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Horm Cancer, 2014, 289(24):17195-202

PubMed: 24778185 ( click the link to review the publication )

Exp Mol Pathol, 2014, 97(1):154-165

PubMed: 24984270 ( click the link to review the publication )

Biomicrofluidics, 2014, 8(3):034104

PubMed: 24926389 ( click the link to review the publication )
Langenbecks Arch Surg, 2014, 10.1007/s00423-014-1235-1

PubMed: 25070024 ( click the link to review the publication )

J BUON, 2014, 19(2):466-73

PubMed: 24965408 ( click the link to review the publication )

Korean J Parasitol, 2014, 52(4):439-41

PubMed: 25246725 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277177 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2014, 88(4):947-54

PubMed: 24606853 ( click the link to review the publication )

University of Alberta, 2014, Yahya Muhammad Fiteih

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(13):4765-78

PubMed: 24946858 ( click the link to review the publication )

Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

JBUON , 2014, 19(2): 466-473

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Ann Oncol, 2013, 24(2):362-9

PubMed: 22967992 ( click the link to review the publication )

Neuro Oncol, 2013, 15(11):1469-78

PubMed: 24101737 ( click the link to review the publication )

J Cell Biol, 2013, 201(2):279-92

PubMed: 23589494 ( click the link to review the publication )

Sci Signal, 2013, 6(279):ra45

PubMed: 23757022 ( click the link to review the publication )

J Clin Endocrinol Metab, 2013, 98(6):2502-12

PubMed: 23559083 ( click the link to review the publication )

Mol Cancer Ther, 2013, 13(2):444-53

PubMed: 24258346 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(11):2541-58

PubMed: 24026012 ( click the link to review the publication )

Mol Oncol, 2013, 7(1):121-9

PubMed: 23127547 ( click the link to review the publication )

Carcinogenesis, 2013, 34(9):1994-9

PubMed: 23677069 ( click the link to review the publication )

Cell Prolif, 2013, 46(4):447-56

PubMed: 23829318 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):473-8

PubMed: 23891090 ( click the link to review the publication )

J Biol Chem, 2013, 288(48):34930-42

PubMed: 24142702 ( click the link to review the publication )

Drug Metab Dispos, 2013, 10.1124/dmd.113.054189

PubMed: 24335466 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )
PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62852

PubMed: 23696788 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82625

PubMed: 24349321 ( click the link to review the publication )

Lipids Health Dis, 2013, 12:101

PubMed: 23849180 ( click the link to review the publication )

Exp Mol Pathol, 2013, 94(2):386-97

PubMed: 23399805 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Genet Syndr Gene Ther, 2013, 4

PubMed: 25520884 ( click the link to review the publication )

Herpesviridae, 2013, 4(1):1

PubMed: 23342981 ( click the link to review the publication )

Oncotarget, 2013, 4(10):1698-1711

PubMed: 24091605 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):1908-16

PubMed: 22722337 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Oncogene, 2012, 32(34):4034-42

PubMed: 22964644 ( click the link to review the publication )

Cancer Lett, 2012, 321(2):187-94

PubMed: 22343320 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 2):435-48

PubMed: 22357970 ( click the link to review the publication )

Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Biochem Pharmacol, 2012, 84(4):425-31

PubMed: 22634404 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

Int J Oncol, 2012, 41(3):869-75

PubMed: 22752005 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51549

PubMed: 23272116 ( click the link to review the publication )
Oncotarget, 2012, 2(12):1134-44

PubMed: 22193779 ( click the link to review the publication )

Mol Syst Biol, 2011, 7:486

PubMed: 21525872 ( click the link to review the publication )

Oncogene, 2011, 30(6):737-50

PubMed: 20890302 ( click the link to review the publication )

Antivir Res, 2011, 89(1):64-70

PubMed: 21094187 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Mol Biosyst, 2011, 7(12):3223-33

PubMed: 21956701 ( click the link to review the publication )

Exp Mol Pathol, 2011, 91(1):400-10

PubMed: 21565184 ( click the link to review the publication )

Vet Comp Oncol, 2011, 11(2):124-39

PubMed: 22235915 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Features

A potent EGFR tyrosine kinase inhibitor.

Targets

Tyr1173 (NR6W cells) ^[1]	Tyr1173 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6wtEGFR cells) ^[1]	Tyr992 (NR6W cells) ^[1]
26 nM	37 nM	37 nM	57 nM

In vitro

Gefitinib effectively inhibits all tyrosine phosphorylation sites on EGFR in both the high and low-EGFR-expressing cell lines including NR6, NR6M and NR6W cell lines. The phosphorylation sites Tyr1173 and Tyr992 are less sensitive requiring higher concentrations of Gefitinib for inhibition. Gefitinib effectively blocks the phosphorylation of PLC-γ, with IC50 of 27nM, in NR6W cells. The NR6wtEGFR and NR6M cell lines has low levels of PLC-γ phosphorylation but the level in the NR6M cell line is more resistant to inhibition by Gefitinib with IC50 of 43 nM and 369 nM, respectively. Gefitinib inhibits Akt phosphorylations, with IC50 of 220 and 263nM, in the low-EGFR- and -EGFRvIII-expressing cell lines, respectively. Gefitinib in the dose range from 0.1 to 0.5μM significantly facilitates, rather than abrogates, colony formation of NR6M cells. However, at a concentration of 2 μM Gefitinib completely blocks NR6M colony formation. Gefitinib rapidly and in a dose-dependent manner inhibits EGFR and ERK phosphorylation up to 72 hours after EGF stimulation in both the high- and low-EGFR-expressing cell lines. ^[1] Gefitinib is the monolayer growth of these EGF-driven untransformed MCF10A cells with an IC50 of 20 nM. ^[2] The combination of Gefitinib (0.2 μM and 0.5 μM) with irradiation lead to a significant growth inhibition in LoVo cells, compared with radiation alone.. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1975	M4jDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmKyTWM2OD1{MT60OlEh\|ryP	NHHZRZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HT	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFq2VWJKSzVyPUKxMlQ{OzFizszN	NGfs[\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HUTU-80	M3fuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonFTWM2OD1{MT60N\|M3KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
PA-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJzLkK3PFch\|ryP	MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HOP-62	NFrGNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFe5T3dKSzVyPUKxMlI4QDRizszN	NEL2[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
GI-1	NHXHWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYX5R5pkUUN3ME2yNU4yPyEQvF2=	Mn62QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MC116	MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn[yTWM2OD1{MT6wO\|I{KM7:TR?=	M3PtUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A375	NFvyO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJzLkC1Olch\|ryP	MlPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
IST-SL1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M360O2lEPTB;MkCuO\|g4QSEQvF2=	NHjGbJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-5	NFHDOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnoUoNKSzVyPUKwMlc1QDJizszN	M{SzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SiHa	M1;BZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{mxPWlEPTB;MkCuN\|cyOiEQvF2=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LB2518-MEL	NGXqOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJyLkO3N\|kh\|ryP	NGLvc\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BB49-HNC	NXjZbnBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF7LkmyJO69VQ>?	Mo[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HGC-27	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJyLkGzPVQh\|ryP	NUL5V492RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
Becker	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PaTWlEPTB;MUmuPFU1PyEQvF2=	NWPiUYV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TYK-nu	NEHteWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LNN2lEPTB;MUmuPFM4QCEQvF2=	M3;NUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H650	NEHPb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TleWlEPTB;MUmuO\|UxQCEQvF2=	NWLne4c{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
WM-115	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLrXWVKSzVyPUG5MlY4PzRizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HuH-7	M17ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mom5TWM2OD1zOT63OFIyKM7:TR?=	MoP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-N87	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PnfGlEPTB;MUmuOVk6OiEQvF2=	MkHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1048	NIrsSZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XpemlEPTB;MUmuNlMzPiEQvF2=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H446	NF\Te3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfMTWM2OD1zOT6zOVg6KM7:TR?=	NEXScmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1437	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjUSnNZUUN3ME2xPU4xPDZ5IN88US=>	NWjNXYc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
D-263MG	NWTrRndNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XhZWlEPTB;MUmuNFE4OiEQvF2=	M{PVVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MFH-ino	M4LFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzCcm5KSzVyPUG4Mlk3PjlizszN	M1e5dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
U-266	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUW1VIF5UUN3ME2xPE45PjR7IN88US=>	NVL0O3ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OVCAR-8	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV7zfGJsUUN3ME2xPE46Ojd4IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KNS-42	NUPMcZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2i5[WlEPTB;MUiuPFAyPSEQvF2=	MmTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
U251	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVXxUpFSUUN3ME2xPE44OzR5IN88US=>	NIr6RVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MFE-280	M3Kxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF6LkeyPVMh\|ryP	M2P2dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1563	NYmwRWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;GTWM2OD1zOD63NVI1KM7:TR?=	NHvTOWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MDA-MB-361	NVPsToo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnX0TWM2OD1zOD61OVg5KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HLE	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfmcFVKSzVyPUG4MlMyPDhizszN	M4jycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW982	NUDJfm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXETWM2OD1zOD60NFc2KM7:TR?=	M{nXblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KM-H2	NHnWXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHX5N49KSzVyPUG3Mlk1OTFizszN	MlrJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
D-502MG	M{\sVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEO2R5RKSzVyPUG3Mlk5ODhizszN	Ml35QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ES8	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXHUJNQUUN3ME2xO{45PTl\|IN88US=>	NWntcpk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SF268	NUjGd3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfrNXVLUUN3ME2xO{43QTZ7IN88US=>	NILreWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Calu-6	M2DkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGH5OpdKSzVyPUG3MlY4QDJizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW1783	M3:4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXW5VFdZUUN3ME2xO{43PDF3IN88US=>	NULPSWtFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H747	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTF5LkWyPVch\|ryP	NYLXVIRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1573	NVKwdmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPRTWM2OD1zNz6yPFI3KM7:TR?=	NV7TOIVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1581	NYLqcoFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTF5LkS0NVEh\|ryP	NVezemVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RKO	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILteWhKSzVyPUG3MlA4PDhizszN	M3Xyc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MZ2-MEL	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jldmlEPTB;MUeuNVM{KM7:TR?=	M{\QZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
GI-ME-N	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULZW241UUN3ME2xOk46ODN{IN88US=>	Ml7yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LB373-MEL-D	M{Kybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHnVVlDUUN3ME2xOk44OjN{IN88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MEL-HO	MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPXVG1bUUN3ME2xOk45QDV2IN88US=>	M2LaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BEN	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fjeGlEPTB;MU[uOVE2PSEQvF2=	M{nnUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
M059J	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTF4LkK4OEDPxE1?	M2\SU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
D-283MED	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfUUHJKSzVyPUG2MlQzODlizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GP5d	NU\GZ3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFy0OmNKSzVyPUG2MlIyQDdizszN	NXr6dVNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BHT-101	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnGUo14UUN3ME2xOk4zPDN7IN88US=>	M1vLZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HT55	MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWixTllxUUN3ME2xOU46PDd6IN88US=>	NUXsWHBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
no-11	NIjsW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rIfmlEPTB;MUWuPVY3OyEQvF2=	M4i4SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MPP-89	M1e0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NETLcVJKSzVyPUG1Mlk1OTdizszN	NHTWZoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuCCT1	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPmTWM2OD1zNT64O\|Qh\|ryP	M2HUdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H23	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfnOW5KSzVyPUG1Mlg1OzhizszN	MoTmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
UMC-11	NYjXS5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\zTWM2OD1zNT63OVI{KM7:TR?=	NVPKTYloRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MCF7	M2CwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\VTWM2OD1zNT64NVQ2KM7:TR?=	NUf0Unc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COLO-320-HSR	NYq4fYxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILW[HJKSzVyPUG1MlU{ODdizszN	M{DUZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CW-2	NIfzTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF3LkG0NlEh\|ryP	MoLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MOLT-4	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLpTo5tUUN3ME2xOU4xPDl5IN88US=>	MnzFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1755	MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT1TWM2OD1zND65PVU{KM7:TR?=	NHry[Yc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MIA-PaCa-2	NWLSd4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvLTWM2OD1zND65Olkh\|ryP	MmW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TGBC1TKB	NITpUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHzZnFjUUN3ME2xOE43PjF3IN88US=>	NXTLfIpHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H630	NFPxdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPHTWM2OD1zND65OFY4KM7:TR?=	NGHLVXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LAN-6	NV\DW3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7PeVJKSzVyPUG0MlI2OyEQvF2=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A549	M4fSd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hkb2lEPTB;MUSuOFcyOiEQvF2=	M3HQWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RD	NVHxSHlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\id2lEPTB;MUSuOFgyOyEQvF2=	NWfiNohiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KALS-1	MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHBfFlKSzVyPUGzMlg2OjVizszN	NGTJSnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LOXIMVI	Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTF\|Lk[xOVEh\|ryP	M3uyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-PN-DW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrDTWM2OD1zMz64OFI4KM7:TR?=	NFnHSYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SN12C	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4mycGlEPTB;MUOuN\|gxQCEQvF2=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1993	NVH3PZdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEi3UIVKSzVyPUGzMlQzQDVizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
G-361	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;5XGRKSzVyPUGyMlkyOjlizszN	Ml;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RH-18	M4q0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPvTWtTUUN3ME2xN{4zQTZ{IN88US=>	MmD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
GT3TKB	MorwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTF{Lk[zNlch\|ryP	NWixd5VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DMS-273	M2jBXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF{Lki2N\|Mh\|ryP	NEXOcZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
C3A	M1P3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rXfWlEPTB;MUKuOVc5PSEQvF2=	Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Daoy	NITTcHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTF{LkS1OFIh\|ryP	MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ABC-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\yTWM2OD1zMj6zOFEh\|ryP	Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KS-1	MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\PTWM2OD1zMj6yPFMzKM7:TR?=	NEfkfZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
JAR	NEfHOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPoTWM2OD1zMj6zN\|Y6KM7:TR?=	NFzQRYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAMA-1	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XyW2lEPTB;MUKuNVY{OyEQvF2=	NYjHcFkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
U-118-MG	NHnmbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTF{LkK0OFEh\|ryP	M2nEZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OE19	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1nTdmlEPTB;MUGuPVM3PyEQvF2=	MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Mo-T	NYW5d2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFzLkm1OFEh\|ryP	M{TZOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SCC-9	NGqxfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1zsZmlEPTB;MUGuPFE2OSEQvF2=	NGDPNlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HOS	NVHsdnJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPHTWM2OD1zMT64Olg{KM7:TR?=	M2jxOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
UM-UC-3	NH;ldoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFzLke0NlEh\|ryP	M4e1S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MMAC-SF	NEjYdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDwWZZKSzVyPUGxMlczPTJizszN	NXL5RpM2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MLMA	NGXIT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX33dYZvUUN3ME2xNU43QTl5IN88US=>	NFGzZm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RPMI-7951	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTFzLk[zOFgh\|ryP	NYnEcYZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H1299	NFe5fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvrTWM2OD1zMT62OlQ4KM7:TR?=	NHP1[Xc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LS-411N	NETHcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYD0U\|N7UUN3ME2xNU43OTBzIN88US=>	NHnhfVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1954	NFnzWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;RTWM2OD1zMT60N\|Yh\|ryP	MlrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
GOTO	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;UeWlEPTB;MUGuOVIxPiEQvF2=	NYPYUmVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
FTC-133	MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXqdZpXUUN3ME2xNU4{ODhzIN88US=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LB831-BLC	NWHsfJlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;CTmlKSzVyPUGxMlI2PTZizszN	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC38	M2\EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTFyLkm3NVYh\|ryP	NHrQVoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SF-295	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PTeWlEPTB;MUCuPVkxOiEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
K-562	NYHt[ZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n5b2lEPTB;MUCuPFM6PSEQvF2=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW900	NVTaSVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vyc2lEPTB;MUCuPFIzQCEQvF2=	NWLYeXdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
D-336MG	M4rkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTFyLkewNFUh\|ryP	M1LrS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LXF-289	MlXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHYTWM2OD1zMD63PVY4KM7:TR?=	M32yblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SW962	NFfXV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3e4XWlEPTB;MUCuOlIxPCEQvF2=	MmPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
VMRC-RCZ	NUH5O5cxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFyLk[3OFkh\|ryP	MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HEC-1	NGDXb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX;JWXUxUUN3ME2xNE41ODhzIN88US=>	M1L0d\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A2058	MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3a[mNKSzVyPUGwMlU1QTFizszN	NYLISFdURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
K5	Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFT2WJZKSzVyPUGwMlM{QTVizszN	Mn;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
U031	NGThXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFyLkK2PFYh\|ryP	MoXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
YH-13	NWfsfmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTFyLkOwOVch\|ryP	NGnr[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-UT-1	NHrYeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2S5[GlEPTB;MUCuNlU4PCEQvF2=	M{ntN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H810	M3jQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3i4UGlEPTB;MUCuNVU6PyEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DJM-1	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTFyLkG3N\|Ih\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAL-51	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFyLkC4O\|ch\|ryP	NUm2NYdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCE-4	NGfCcnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DDW2lEPTB;MUCuNVEzOiEQvF2=	MmnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2342	MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDNTWM2OD1zMD6wNVU2KM7:TR?=	NITZOGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A204	NGfOSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4P4SGlEPTB;MUCuNFQ3PiEQvF2=	NG[0Ros9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1355	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\vVpJKSzVyPUmuPVQxQDhizszN	NXL6RnRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SW837	NVu0bZlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MonaTWM2OD17Lki0PFIh\|ryP	NU\BVFB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
OCI-AML2	NHjrNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr0TWM2OD17Lki2PVYh\|ryP	M3LySVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EFO-21	NWLafZYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn3JTWM2OD17LkW4O\|M2KM7:TR?=	MkH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
C32	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXT3UlV{UUN3ME25MlY{OzRizszN	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KP-4	NGjBW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrWdmN3UUN3ME25MlQ5QDN6IN88US=>	NHHrS3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A101D	M{\3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTlwNUG3NVkh\|ryP	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
IA-LM	NGPaUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWS2NZVZUUN3ME25MlQyQTZ4IN88US=>	MoTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HPAF-II	NX\aN44zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojwTWM2OD17LkKyOVE5KM7:TR?=	NIrwbpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Capan-2	NYDUeVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrJb2NsUUN3ME25MlQxOTB7IN88US=>	M3vDe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BFTC-909	NFzDV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\tUYFKSzVyPUmuNVgzQTdizszN	M{fhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RPMI-8226	NUnhNllKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVT0PWZwUUN3ME25MlEyOzB2IN88US=>	NX;sOZA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
ChaGo-K-1	NYTmUJc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH25dlRKSzVyPUmuNVA2PzlizszN	M3zCSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H2228	Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTlwMUGwPFEh\|ryP	NGDNRoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H226	M1P0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTlwMEmg{txO	NXTrOYtuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
D-566MG	MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILXXYhKSzVyPUmuNFE5OSEQvF2=	NHXVfIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LS-1034	NWC4d4NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjE[WVKSzVyPUiuPVQ3PTJizszN	NE\TfYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1792	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nne2lEPTB;OD64PFkxOyEQvF2=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-792	NUSx[IQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LSZ2lEPTB;OD63OFk1PiEQvF2=	NF3NS\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A673	M{i2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRThwNke2NVEh\|ryP	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
D-392MG	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRThwNk[yNVQh\|ryP	M2jJWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EGI-1	NEO1e5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnaXJJKSzVyPUiuOlAxQDhizszN	NHLQO\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TGBC11TKB	NVfEO3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrQOXc6UUN3ME24MlQ3OTZ2IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
5637	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3ruemlEPTB;OD6zNVA2PSEQvF2=	MkXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-70	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHmeIU2UUN3ME24MlE6PzZzIN88US=>	NUewO3dvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	NGfRWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEfxNoNKSzVyPUiuNVcxOjlizszN	NHmyToY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
AM-38	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRThwMU[yPEDPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H661	NHSz[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfUbW1KSzVyPUiuNFU5PjdizszN	NILrdJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SHP-77	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\2d4xVUUN3ME23Mlg3PjV\|IN88US=>	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DK-MG	M{Lv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfGZldKSzVyPUeuPFMzODFizszN	MlzZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NB13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljKTWM2OD15LkiyOlY4KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
COLO-829	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH0fVVKSzVyPUeuOlY1PjNizszN	M4H0ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
OS-RC-2	NG\CcGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[3TWM2OD15LkS5PFk1KM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC1419	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Owe2lEPTB;Nz60Olg{OyEQvF2=	M33HRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SKG-IIIa	NYO0ZldlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTdwNEWzPFEh\|ryP	M3\QN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COLO-668	M{TYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTdwNEO5Olch\|ryP	M3GyN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-62	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorkTWM2OD15LkO5PFY3KM7:TR?=	NI\HT5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HEL	M33EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7hZplKSzVyPUeuN\|c2OjFizszN	M{XSOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H2030	NIL5eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HrV2lEPTB;Nz6zN\|Y6QCEQvF2=	NEj5UYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DMS-114	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\hc25KSzVyPUeuNlk3OzFizszN	NIDRWXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NOS-1	NV7UTpJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV[4Oos4UUN3ME23MlI2QDJ6IN88US=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KP-N-YS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7GT3hKSzVyPUeuNVgyPCEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OVCAR-4	NGrTZ5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDNTWM2OD15LkG1N\|Uh\|ryP	NVvCW243RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2405	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfwOoo5UUN3ME23MlA5Ozl\|IN88US=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-11	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLQTWM2OD15LkC0PVY4KM7:TR?=	NEjWdGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KLE	Mn:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXzc3NKSzVyPU[uPVY2OTZizszN	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A388	M3TkOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUG5PYw4UUN3ME22Mlg6PTJizszN	NUe2eGd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB12	NFjCdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTZwN{i0NFQh\|ryP	Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PFSK-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVywXIYzUUN3ME22Mlc{PDd6IN88US=>	M2W0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-HEP-1	NUfLXIFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTZwN{G3OVMh\|ryP	M4jQfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
Calu-3	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDQSYVDUUN3ME22MlY2PTZ6IN88US=>	M3mz[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SH-4	MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTZwNUi4OFQh\|ryP	NV\UdVVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GCT	NHjiPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;Db5JKSzVyPU[uOVM{QDdizszN	Ml3FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MSTO-221H	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO3fmN7UUN3ME22MlUyOTdizszN	NVfOemJxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
GAMG	NXTXcFI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1r3fWlEPTB;Nj61NFYzKM7:TR?=	NGnkd449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAL-120	NUTRNVBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFG1S5RKSzVyPU[uOFUyPjJizszN	Mn[2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
VA-ES-BJ	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjxTWM2OD14LkOwOFYzKM7:TR?=	NFzreIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-MEL-28	M1TwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTZwMkC5Olch\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
8-MG-BA	NUnEdXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXDfYJKSzVyPU[uNVk{PzlizszN	MlXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
L-428	M{XDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTZwMUiwN\|ch\|ryP	MlLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Mewo	NWrHNGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjJelEyUUN3ME22MlEyPDh5IN88US=>	NF\2TFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
RCM-1	M2TtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fvVWlEPTB;Nj6wO\|cyQSEQvF2=	NIexeYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KE-37	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\RVGlEPTB;Nj6wO\|I2QCEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TE-10	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLMTWM2OD14LkC0PFM{KM7:TR?=	NXvWTmJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HDLM-2	NEnJU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXxeWFKSzVyPU[uNFE1QDlizszN	NETte5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
CAKI-1	M4mzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\1V2FKSzVyPU[uNFA6QDVizszN	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RT-112	NGTJVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHMZ4xxUUN3ME21MlkxOjR3IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC2998	M1y3OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXLTWM2OD13LkexPFc4KM7:TR?=	NGHweYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1187	NV71XWplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmf3TWM2OD13LkexNFMzKM7:TR?=	NXvZfJk2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HD-MY-Z	NH30bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnOwTWM2OD13Lk[4OVgyKM7:TR?=	Mnv4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RMG-I	M2jUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHr2NXdKSzVyPUWuOlU6PDJizszN	NVjkOoQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BFTC-905	NXr5XGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTVwNkW4O\|gh\|ryP	Mli3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1990	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nHdmlEPTB;NT62NlI5PSEQvF2=	NHm1fG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW13	M{DOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLJV5lKSzVyPUWuOVMzPjVizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
AGS	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TUT2lEPTB;NT60PVYyQCEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ATN-1	NXjBNlVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrOflZKSzVyPUWuOFEyQDRizszN	M4fUOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CGTH-W-1	NIKxbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXEOWlKSzVyPUWuN\|g2QDRizszN	NFjvfoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NOMO-1	NUXKfXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTVwMkOxO\|Yh\|ryP	MnLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ALL-PO	NEfWSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPMTWM2OD13LkKyOVg4KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KP-N-YN	NUP0TXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXYcWNKSzVyPUWuNVI2QTFizszN	Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1838	NI[0NHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r5c2lEPTB;NT6wNlA4PiEQvF2=	M1PtdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-9	NXLFNpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXG3WVJRUUN3ME21MlAyPTJ3IN88US=>	Mnf6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KOSC-2	NVPR[2tbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XaN2lEPTB;ND65PVk2QSEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ES1	NXLEcIV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnxTI9KSzVyPUSuPVYxOzVizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KNS-62	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTRwOUC4NFch\|ryP	NITkXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KYSE-520	NX\wWnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTRwOEiwNVgh\|ryP	NH;kdVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
P30-OHK	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXSeWRKSzVyPUSuPFE6OjlizszN	MnT5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NB10	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXpTWM2OD12LkW5O\|gyKM7:TR?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A172	NUXyOph7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTRwNUW1NlEh\|ryP	NFm1Wnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-OV-3	M1Wy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYL0U2pKUUN3ME20MlQ3ODR{IN88US=>	M{nNe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
GR-ST	NWr5PIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\sT3BKSzVyPUSuOFMyQCEQvF2=	NWmwd5g3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC1937	Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTRwM{e5PVMh\|ryP	M4K1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
LU-139	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTRwM{eyOFch\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SNU-C2B	M2LBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHCPJpKSzVyPUSuN\|Q3QDZizszN	M4XRXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KARPAS-299	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHviTIxKSzVyPUSuN\|ExOTNizszN	Mm\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EW-11	NWfGSGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoDETWM2OD12LkGzNlYyKM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HL-60	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTRwMUKyOFEh\|ryP	MnzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TCCSUP	NITB[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M334NWlEPTB;ND6xNVA2KM7:TR?=	NW\pSYJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RCC10RGB	MkXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TJdGlEPTB;ND6wNVI1PiEQvF2=	MnmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H441	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PifmlEPTB;Mz65O\|AyPCEQvF2=	M4HwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EW-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTNwOUW1O\|ch\|ryP	M1LYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
JVM-2	M4LEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTNwOUS3OVIh\|ryP	MlLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NH-12	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\pXnZKSzVyPUOuPVQyQDdizszN	MlyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
IST-MES1	NFTzdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTNwOUSwNlkh\|ryP	M3XuVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H69	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGC5Z3JKSzVyPUOuPVAyPzhizszN	M1rBdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KURAMOCHI	M33oe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3LyTmlEPTB;Mz64OlA2PiEQvF2=	NFnDVlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1155	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHyTWM2OD1\|Lki0NVU6KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H28	NXnBVWNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK2TWM2OD1\|LkiyPVYyKM7:TR?=	MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ES4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHkTWM2OD1\|LkiyNlg3KM7:TR?=	NWrQOJBORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NXPsOJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjvTWM2OD1\|Lke1OFA3KM7:TR?=	Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
PANC-10-05	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TndWlEPTB;Mz63NlA4OiEQvF2=	NG\XNFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-MES-1	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjPVmlIUUN3ME2zMlY1PjF2IN88US=>	NH7V[Ww9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
C2BBe1	NFLIeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTNwNkS0NFch\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
A2780	NELFUYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTNwNkSwPFkh\|ryP	Mn;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CaR-1	NX;COnFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfYTWM2OD1\|Lk[xNFQ5KM7:TR?=	MljZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-LU-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M362Z2lEPTB;Mz62NFY1PSEQvF2=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OAW-28	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3WTWM2OD1\|LkW5OFI3KM7:TR?=	M2HMUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
TE-1	M{OwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTNwNUmxOlkh\|ryP	M3XwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
639-V	NIWwPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVe5[W9JUUN3ME2zMlU4Pzl{IN88US=>	NYCzeFVFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
C8166	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3iSoFKSzVyPUOuOFY2OjFizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NTERA-S-cl-D1	NUTESXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml73TWM2OD1\|LkS0PVU4KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
D-542MG	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXO3[HZ2UUN3ME2zMlQ1OjJ{IN88US=>	MorJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LB771-HNC	M4rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljRTWM2OD1\|LkO5NVI3KM7:TR?=	M4fiNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H727	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDDW2lyUUN3ME2zMlM5PTh2IN88US=>	MmGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1463	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHRd444UUN3ME2zMlI3OTl{IN88US=>	MmS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1793	NY\4Zo5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkDxTWM2OD1\|LkKxNFk5KM7:TR?=	M2T1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HT-1376	NXrDVXJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrpR3UzUUN3ME2zMlIxPTB4IN88US=>	NETsb2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
647-V	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTNwMU[yNkDPxE1?	MlXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BCPAP	NEnXV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHflTFJKSzVyPUOuNFgzQTVizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MN-60	NWqzSGhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVjJR\|UxRTNwMES5O\|Qh\|ryP	NX3rbHFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COLO-680N	NUDid5RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTNwMEC0PVUh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DU-4475	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvxXHBKSzVyPUKuPVkxPTJizszN	NF[5WmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1693	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjIV\|JKSzVyPUKuPVU5QTdizszN	NUnDTWJXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HC-1	NWf5d2szT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\Mc4ttUUN3ME2yMlk1ODF{IN88US=>	MnGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KYSE-510	NFXuW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRTJwOE[3PFYh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
OVCAR-3	MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnkS\|dKSzVyPUKuPFU2QTRizszN	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
PC-3	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MluyTWM2OD1{LkizN\|E4KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BB65-RCC	MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DReGlEPTB;Mj64NFcyOyEQvF2=	M1v0N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
QIMR-WIL	Mom1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTITWM2OD1{Lke1PVUzKM7:TR?=	NXXQfVVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HuP-T4	M3nNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonJTWM2OD1{LkeyPFE5KM7:TR?=	MmToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Detroit562	M4TKPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFO0R4lKSzVyPUKuOlk5PDVizszN	NEfZSGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DMS-79	M17OOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[z[WlEPTB;Mj62PVI5PCEQvF2=	NVK2V3BxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MC-IXC	MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;pXGlEPTB;Mj62OFQ2OyEQvF2=	Mni0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TE-8	NWjxTHJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1nDSmlEPTB;Mj62N\|Y2OyEQvF2=	NUPpcG9NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MKN7	Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPnOZR1UUN3ME2yMlYzPzR6IN88US=>	MmXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HH	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTJwNEm4OVQh\|ryP	NUnZT3RQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CFPAC-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwNEO4OlQh\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HTC-C3	NEHjeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTJwNEKyOlch\|ryP	NVPPZVIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NY	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTJwM{eyO{DPxE1?	NFzRc2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KU812	NFvpWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33MSWlEPTB;Mj6zOlc4QSEQvF2=	NYP6dXJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
EW-18	M2TIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfJc45CUUN3ME2yMlM2PDdzIN88US=>	NYfHWYI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2170	M{PWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;peZZKSzVyPUKuN\|Q4QDNizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
JVM-3	NXXsXHBUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\jcGlEPTB;Mj6zOFY1OyEQvF2=	NWriUWFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
IGROV-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwM{GyN\|ch\|ryP	M3jUc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
A498	NFj5XVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XsOWlEPTB;Mj6yPVQyPSEQvF2=	NHHtZ3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BT-20	Ml\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnNXm9NUUN3ME2yMlI3PzR2IN88US=>	NET4UI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SCC-4	NV;RUWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJwMkG3O\|Yh\|ryP	M4\6flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
786-0	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jUR2lEPTB;Mj6xPFQxPiEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
RXF393	NWTzd5p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEL3fW1KSzVyPUKuNVMxOzZizszN	M2DuNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KARPAS-45	NHjaUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTJwMUK0O\|kh\|ryP	NVvJdVNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
RPMI-8866	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYe2PHRNUUN3ME2yMlA5PDhzIN88US=>	NUDnO4g6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2009	MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmK5TWM2OD1{LkC2NlE1KM7:TR?=	MlXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SW1116	NXvjOJByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTJwME[wNFkh\|ryP	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EKVX	M1XW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTJwMES5N\|kh\|ryP	NXzkOph{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
TGBC24TKB	NWP6V49QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfrXlNKSzVyPUKuNFI6PjFizszN	NXXsS5hsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAL-12T	NIPUdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rPd2lEPTB;Mj6wNVg3OSEQvF2=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC70	NFzGOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJwMEC4NVUh\|ryP	NF70UVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
OMC-1	NXnHWIIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7aTWM2OD1zLkm5PFg5KM7:TR?=	NH\zd2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EPLC-272H	M{TWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTFwOEW1OFkh\|ryP	MnqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H209	NI\INXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTFwN{eyOlkh\|ryP	M3HSWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1666	NGrCdG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTFwN{S3NFQh\|ryP	NYDkZ5AyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
COLO-678	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M36yNmlEPTB;MT63N\|Q1PCEQvF2=	NEDDfIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PANC-03-27	NXjafYJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYH3ZVVnUUN3ME2xMlcxOTN7IN88US=>	NYDoc3FTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BB30-HNC	Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{izXmlEPTB;MT62PFk4OiEQvF2=	NFSwNlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ML-2	NEn1dJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTveY1KSzVyPUGuOlQxOjlizszN	NISxZWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
BT-549	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3QXGFKSzVyPUGuOVg4PDdizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-3	M1\Ye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTFwNUSzPEDPxE1?	NFy5b3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
LAMA-84	MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHrSG55UUN3ME2xMlU{QDF3IN88US=>	NF3iOJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SCC-25	NWPNOVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTDcXpwUUN3ME2xMlUzOzJ{IN88US=>	NXPoWZRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SAS	MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULz[Xh2UUN3ME2xMlUyPjJ{IN88US=>	M1m1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BE-13	NFXiRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX[2cIQzUUN3ME2xMlUxPjdzIN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
J82	NFK4T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXX1eGd6UUN3ME2xMlQ2PzZ4IN88US=>	NF3aUGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
697	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zvNGlEPTB;MT60OFExPCEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H526	NFPwZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwNEO4NlYh\|ryP	MnrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
RH-1	M4PQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmT1TWM2OD1zLkSxNVM3KM7:TR?=	Ml7VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CCRF-CEM	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTFwNEGxNUDPxE1?	NVzLbXBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NB5	NUXESFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPHe5N5UUN3ME2xMlQxQDl2IN88US=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
KMOE-2	NV\pWnhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zhO2lEPTB;MT6zPVgyPSEQvF2=	MlHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SK-N-DZ	NWHQN41bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPCXYo4UUN3ME2xMlM3QTR5IN88US=>	NH;IO3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW48	M160emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvWNnNKSzVyPUGuN\|Y3OThizszN	NFfq[m49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW954	NGO4RoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwM{SwOFgh\|ryP	NIP1[G49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
NCI-H1650	M3;hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2joZmlEPTB;MT6zN\|Q5OiEQvF2=	MmDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NKM-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTFwM{K1PVch\|ryP	M1HDW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1092	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnBbZNKSzVyPUGuN\|A5PSEQvF2=	NWTuenJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CTV-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DBUWlEPTB;MT6zNFgh\|ryP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
GCIY	M2C0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnxTWM2OD1zLkOwNVMzKM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW1088	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\iNWlEPTB;MT6yPVYxPyEQvF2=	NFvmPWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
769-P	MnHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnOxTWM2OD1zLkK3PVE5KM7:TR?=	MnzLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
OAW-42	M3;VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PGZmlEPTB;MT6yO\|gzPSEQvF2=	NGfhcVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SNU-449	NICzcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LwbGlEPTB;MT6yNlIxQCEQvF2=	M1\S[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
MKN1	NYW2OohlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHwfGRKSzVyPUGuNlE6QDdizszN	Mo\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H1648	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTuTWM2OD1zLkGwOlE3KM7:TR?=	M1f5NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KU-19-19	M4TycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX71TotzUUN3ME2xMlA5PTRzIN88US=>	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
MHH-PREB-1	M4T0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXTJR\|UxRTFwMEi0OVEh\|ryP	M1zUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
EM-2	M2ri[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3uzXGlEPTB;MT6wN\|AyPiEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1304	M3rm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGS3c2xKSzVyPUGuNFE3PDNizszN	MmP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DOHH-2	NFTZZ2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4H6SmlEPTB;MT6wNFAzOSEQvF2=	NGDZTpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
MS-1	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjNeY9PUUN3ME25PVQvPjlibl2=	M2LhV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
SK-NEP-1	NV3sNIN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXz5c45mUUN3ME25PFkvPDRibl2=	NWOyS3o4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HT-3	Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{KzWGlEPTB;OUiyMlQyKG6P	M13ESVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
BHY	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPQTWM2OD17N{WuOFghdk1?	Mn7vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BT-474	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDMbmdUUUN3ME25N\|gvOTRibl2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAPAN-1	M1Tuc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTiSmhKSzVyPUi4N{4zQSCwTR?=	MmL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H2126	MojlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUTpSVhCUUN3ME24PFIvQDNibl2=	Ml7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
COR-L88	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTh6Mj6yOkBvVQ>?	NGXHfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DEL	NH75VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTh5Nz62OUBvVQ>?	NUHqdlRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
AU565	NIXtcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\GTWM2OD16NkmuOkBvVQ>?	Ml:yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
23132-87	NGLqTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTUS41KSzVyPUi2OE4zQCCwTR?=	NWG3dI5zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LoVo	Mln4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrnZ5dKSzVyPUi1PU4xPiCwTR?=	NE\WXYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-12	NGqwNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPzfHRKUUN3ME24NlEvOTFibl2=	NHPxdHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EC-GI-10	NVjURVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\yTWM2OD15OEiuOVIhdk1?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LU-135	M3e5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfvNmM6UUN3ME23PFMvODNibl2=	NF3Ze3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
A431	Ml3zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfJc5pKSzVyPUe4NE4xPCCwTR?=	NFu1epA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
TE-6	NFPWWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fLUmlEPTB;N{[0MlMyKG6P	NHX5OWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
COLO-684	M1nESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLtfm9yUUN3ME23OVMvODFibl2=	M{nFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HAL-01	M3OyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4n5WGlEPTB;N{O0MlcyKG6P	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1770	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjRTWM2OD15MkKuOEBvVQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LU-134-A	NIToRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2GyfmlEPTB;N{G5MlA6KG6P	NFzJbGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
L-363	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Pi[GlEPTB;NkexMlk1KG6P	NEfnOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
ETK-1	MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\YcYZQUUN3ME22OlIvPTlibl2=	M2O4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
COR-L105	NFPiUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjjRYVKSzVyPU[2Nk42OyCwTR?=	NWnjNIY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NBsusSR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG5TWM2OD14NE[uOVIhdk1?	MofmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ME-180	Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnHeFZEUUN3ME22N\|IvQSCwTR?=	M3frclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
DBTRG-05MG	MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\CWZFKSzVyPU[zNk4zQCCwTR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MV-4-11	NY[yO\|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rhO2lEPTB;NkK3Mlchdk1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
LB1047-RCC	MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrtSY41UUN3ME22NlUvOjlibl2=	NGe5NVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	M3LYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDCXld5UUN3ME22NlEvPDZibl2=	MlPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NB69	M3vyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTXdYVuUUN3ME22NVQvOzVibl2=	MkfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
FADU	M4D5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTZyND62PUBvVQ>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H1623	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O0[GlEPTB;NUm5MlM3KG6P	Mne3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CAL-39	M3\5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHBTWM2OD13OU[uN{BvVQ>?	MlflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
Ca9-22	MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTV6OD62OEBvVQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
CAN	NXP4bIlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjTTWM2OD13OECuO\|Yhdk1?	M3\DeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
RS4-11	M3vKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjBWmNKSzVyPUW2PE42QSCwTR?=	MlrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DSH1	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEj1XnBKSzVyPUW2Ok45QCCwTR?=	MknLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NB7	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFiwPJVKSzVyPUW0Ok4{OiCwTR?=	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H82	Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3QPJFPUUN3ME21OFAvPSCwTR?=	NYX6bYNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KYSE-180	NIHqOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4PJW2lEPTB;NUOwMlYzKG6P	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-H358	M2SzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjxTWM2OD13MkeuOlYhdk1?	Mm\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
SCC-15	M33YdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\hcGlEPTB;NUK1MlY5KG6P	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HN	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rKZWlEPTB;NUG3MlM5KG6P	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
TK10	Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf5ZnBKSzVyPUWxOU4yOSCwTR?=	NUH6[W52RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
MOLT-13	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn6yTWM2OD13MUSuPFIhdk1?	NF;idIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SK-MEL-1	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTVzMD65PUBvVQ>?	M1rLVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
HO-1-N-1	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWnJd2hlUUN3ME21NFkvOjVibl2=	M2TkZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-270	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR7OD62OUBvVQ>?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
BPH-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTR7MT6xOkBvVQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EFO-27	M1H6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH2TYpKSzVyPUS1OE44PCCwTR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
DoTc2-4510	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTR2Mj6xNkBvVQ>?	MnPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
CTB-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HFNWlEPTB;NEK0MlQhdk1?	NGnzOnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
KY821	NEfSZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[4TWM2OD12MEiuOVchdk1?	M3X3eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NUGC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLjT\|JKSzVyPUSwNU45OSCwTR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MDA-MB-175-VII	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;1TWM2OD1\|N{iuPFghdk1?	M3zkcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-33	NWDpNIRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTN5MD65JI5O	Mnj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KASUMI-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{n5[mlEPTB;M{[2Mlc{KG6P	Mme3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
ECC10	NGfrXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTN3Mj65OkBvVQ>?	MlK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
A4-Fuk	NETkfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTN3MD6wNkBvVQ>?	NWPZeo9NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SK-MEL-24	NHTk[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;OTWM2OD1\|M{euPFchdk1?	NEDv[\|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HCC1806	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTN\|Nz61NUBvVQ>?	NFvHNGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
PC-14	M4nqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGCzWoNKSzVyPUOzN{41OSCwTR?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
ACHN	NUnWO4xwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TFfGlEPTB;M{OxMlQhdk1?	NYnVfFdyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
P12-ICHIKAWA	M3zGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLWN2M4UUN3ME2zNlgvODZibl2=	MnftQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
TI-73	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\vV5hUUUN3ME2zNVIvPzVibl2=	NVq2V2pDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CAL-54	NE\jWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\MVnRKSzVyPUOxNU4zOyCwTR?=	NV3SW4tURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
SBC-1	NUj1RlFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3:2U2lEPTB;M{C3Mlc6KG6P	NUHsU4RrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
BALL-1	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLTTWM2OD1{OUeuOFIhdk1?	M2fxWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-27	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;BXnViUUN3ME2yPFkvODhibl2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
NCI-SNU-1	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHWyW3dKSzVyPUK4N{4{OiCwTR?=	NUP1RmJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCE-T	NXTuWVB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJ5OT63PUBvVQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MEG-01	M17EXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\leWpKSzVyPUK3Ok44PiCwTR?=	M3r1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CAL-72	M1ztPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\LWVFKSzVyPUK2PE44OyCwTR?=	M3ny[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-450	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJ2Nz65NkBvVQ>?	MmPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
EW-13	NVzEcVJkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIL6OZZKSzVyPUKyOU4yKG6P	NXrJR\|lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
DU-145	NV\SS5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHyTWM2OD1{MUmuNFQhdk1?	M3PNUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
KYSE-140	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4LlUWlEPTB;MkC5Mlk3KG6P	M3nKOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
CHL-1	MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPudFNwUUN3ME2yNFgvPTFibl2=	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
KG-1	MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm1eJJDUUN3ME2yNFQvOzRibl2=	Mm\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LB2241-RCC	M2WwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTF7ND65N{BvVQ>?	MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
BV-173	NGfTXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTF6Nj61OUBvVQ>?	MmLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
LU-65	M4fsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPyTWM2OD1zNk[uOlEhdk1?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzXbJZyUUN3ME2xOlUvPTdibl2=	MniwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-H292	M2WyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDxSXoyUUN3ME2xOlIvPjZibl2=	M2PQPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
H9	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;oTWM2OD1zM{euNkBvVQ>?	NIqyUWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
DOK	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\RZ2lEPTB;OUOuOlIhdk1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HSC-4	M{XnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTZzLkWzJI5O	MkXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
DB	NIDFU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnQUYptUUN3ME22NE46PiCwTR?=	NIjaTIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
HuO-3N1	M3zSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fUfGlEPTB;NU[uNFkhdk1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
HCC2218	NETkVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnHmTWM2OD13MD61PUBvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
EW-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEi0R5dKSzVyPUS2MlA1KG6P	Mmr1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
NCI-SNU-5	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPjPWNZUUN3ME2yPE4yQSCwTR?=	NULqc5FjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H720	NHm3eYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4H6[GlEPTB;Mk[uPVIhdk1?	NIfVNG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
EoL-1	MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTVwMUegcm0>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
MIAPaCa2	NVX6U29DSXCxcITvd4l{KEG\|c3H5	NH:xc\|kzOCEQvF2=	M4HlSVI1KGh?	NEjRd5lFVVOR	NY\BV4di\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyClYYPwZZNmKDNiYXP0bZZifGmxbh?=	MmHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
MIAPaCa2	NUH2fI9PSXCxcITvd4l{KEG\|c3H5	NUO1ZoFGOTBizszN	MmrRNlRpKG:{IES4JIg>	NGPVfmxFVVOR	MoC3[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?=	Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
MIAPaCa2	NGWzUlVEgXSxdH;4bYMhSXO\|YYm=	Mlf2NUDPxE1?	M4D5clExKGR?	NVvlb4FyTE2VTx?=	M3rMOIhieyCwbzDjfZRwfG:6aXPpeJkh[XO\|ZYPz[YQh[XNic4XwdJJme3Orb36gc4Yh[2:ub375JIZwem2jdHnvci=>	MnzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
MIAPaCa2	M3XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;5Nk42KM7:TR?=	NYT5cZZlPzJiaB?=	MomxSG1UVw>?	NHHSSXVp[XNibn:g[5Jwf3SqIHnubIljcXSrb36=	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4NkW1OUc,OjB2Nk[1OVU9N2F-
H1975	M{H4VmtqdmG\|ZTDBd5NigQ>?	M3fj[\|AvPSEQvF2=	MYOyOEBp	NXLKSWNYTE2VTx?=	NGXQR5Zld2W\|IH7veEBqdmirYnn0JGVITlJiTEi1PHIwXDd7MF2gcZV1[W62LX3l[IlifGWmIFHreEBxcG:\|cHjvdplt[XSrb36=	M2DWVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O5N\|QzLz5{MkOzPVM1OjxxYU6=
H1975	MnTJT4lv[XOnIFHzd4F6	NInk[2MxNjVizszN	NGTKNJYzPCCq	NFLOSpVFVVOR	M1TyTYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	NV[3TVNjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzN\|k{PDJpPkKyN\|M6OzR{PD;hQi=>
H1975	MXnLbY5ie2ViQYPzZZk>	MVKwMlEzPSEQvF2=	NYrD[HpZOjRiaB?=	MknHSG1UVw>?	NVrUcoJI\G:nczDuc5QhcW6qaXLpeEBGT0[UIFy4OVhTN1R5OUDNJI12fGGwdDDZNVA3QCCjdYTvdIhwe3Cqb4L5cIF1cW:w	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN\|OUO0Nkc,OjJ\|M{mzOFI9N2F-
H1975	NWLiVFU1U2mwYYPlJGF{e2G7	MkHRNE4{OyEQvF2=	MkLYNkBp	NH3zd2JFVVOR	MkXy[I9meyCwb4SgbY5pcWKrdDDFS2ZTKEx6NUjSM3Q4QTCPIHTveYJt\SCvdYThcpQheGixc4Doc5J6dGG2aX;u	M2TjclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK0PFk5Lz5{NEGyOFg6QDxxYU6=
H1975	MnTyT4lv[XOnIFHzd4F6	M2HYd\|AvOzNizszN	MWiyJIg>	MW\EUXNQ	M3LBRYRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGWkticHjvd5Bpd3K7bHH0bY9v	NWriW2xERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlQ5QThpPkK0NVI1QDl6PD;hQi=>
H1975	NHLZbItMcW6jc3WgRZN{[Xl?	NWTPSJpiOC5\|MzFOwG0>	MX[yJIg>	NF;EeFJFVVOR	M2DiXoRw\XNibn;0JIlvcGmkaYSgSWdHWiCOOEW4Vk9VPzlyTTDkc5VjdGVibYX0ZY51KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBCU1RicHjvd5Bpd3K7bHH0bY9v	M3zrblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK0PFk5Lz5{NEGyOFg6QDxxYU6=
HCC827	MX;LbY5ie2ViQYPzZZk>	NUTUUGtIOC5zMTFOwG0>	NHSzeYQyKGh?	MmrrSG1UVw>?	MmrSbIF{KG6xIHnydoV3\XK\|aXLs[UBqdmirYnn0bY9vKG:oIFXHSnIh[XO\|ZYPz[YQh[XNicnXjc5Zmenlib3[gSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:w	NUfxcXE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlQ5QThpPkK0NVI1QDl6PD;hQi=>
H1975	M2HBPWZ2dmO2aX;uJGF{e2G7	NFG0dGoyKM7:TR?=	NVHhVmZbOjRiaB?=	MXnEUXNQ	NXLLdFZ5\G:nczDuc5QhcW6qaXLpeEBGWkticHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEhzOUe1JINmdGy\|IHjhdoJwemmwZzDFS2ZTKEx6NUjSM3Q4QTCP	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{W5NUc,OjR4MEe1PVE9N2F-
H1975	MofkT4lv[XOnIFHzd4F6	MmPoNUDPxE1?	NF3VWHUzPCCq	NXvZZY5nTE2VTx?=	NXq2bFMz\G:nczDuc5QhcW6qaXLpeEBGT0[UIIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCKMUm3OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4Vk9VPzlyTTDteZRidnR?	Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe1PVEoRjJ2NkC3OVkyRC:jPh?=
LNCaP	MYjGeY5kfGmxbjDBd5NigQ>?	NEHacpMyOCEQvF2=	Mn\xNoghd3JiNDDo	M1XEcWROW09?	MonJ[I9meyCwb4SgbY5pcWKrdDDheZRweGixc4Doc5J6dGG2aX;uJI9nKGmvbYXuc5B2emmoaXXkJIZt[WdvdHHn[4VlKEKveDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{OlCfQWTQ	NH\VV5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2O\|MyOid-MUi2Olc{OTJ:L3G+
A431	MXHLbY5ie2ViQYPzZZk>	NUjOW3VxOSEQvF2=	NYLtUGNsOSCq	MmPGSG1UVw>?	M4DxWohieyCwbzDpdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDFS2ZTKGG3dH;wbI9{eGixconsZZRqd25?	NXS1XmZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA2QTRpPkK0PVAxPTl2PD;hQi=>
NCI-H1975	NH\YVYRHfW6ldHnvckBCe3OjeR?=	MXOxNEDPxE1?	MYS4JIg>	NH3tUXBFVVOR	NInY[Ipld2W\|IH7veEBqdmirYnn0bUBGT0[UIHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHUlugdIhwe3Cqb4L5cIF1cW:w	MnT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzMU[xOlgoRjJ\|MUG2NVY5RC:jPh?=
HCC827	NH7lNZJEgXSxdH;4bYMhSXO\|YYm=	NF3EXG4xNjVizszN	MX:3NkBp	MWDEUXNQ	NUX0PZhxcGG\|IH7vJIN6fG:2b4jpZ4l1gQ>?	NEPYWFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m5N\|MzQCd-MkO5PVM{Ojh:L3G+
HCC827	M3HDOmZ2dmO2aX;uJGF{e2G7	M1z4NFAvPSEQvF2=	NVG0eoIxOiCq	M3jjS2ROW09?	M{CwZYRw\XNibn;0JIlvcGmkaYSgZ{1O\XRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCyNESvOFIheGixc4Doc5J6dGG2aX;u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
HCC827	NYfLTYdCTnWwY4Tpc44hSXO\|YYm=	MXiwMlUh\|ryP	NFz2OXMzKGh?	MoTLSG1UVw>?	Mnv3[I9meyCwb4SgbY5pcWKrdDDjMW1mfCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
SW620	NG[wUJhEgXSxdH;4bYMhSXO\|YYm=		NHLNVJI1QCCq	MnTJSG1UVw>?	NH22b4NKSzVyPUK4MlIh\|ryP	NIfpdYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFU6PCd-MkS5NFA2QTR:L3G+
Sf9	MWPLbY5ie2ViQYPzZZk>		M4nSXlExKG2rbh?=	MnixSG1UVw>?	NXrYZXRmUW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKHKnY3;tZolv[W62IHjpd{11[WepZXSgSWdHWiBqYX3pco8h[WOrZDC2OFUuOTF6Njmg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkCyJO69VQ>?	Mor4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5M{GyPFEoRjJ2N{OxNlgyRC:jPh?=
HepG2	NFS3NJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHrqdmYzPCCq	NX3LbHVNTE2VTx?=	NFTEd2hKSzVyPU[uOFIh\|ryP	M2fXNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{OxNlgyLz5{NEezNVI5OTxxYU6=
Hela	NVL3ZmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGL5fmYzPCCq	NFW1[JFFVVOR	NES2fIZKSzVyPUKuOlch\|ryP	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd\|MUK4NUc,OjR5M{GyPFE9N2F-
NCI-H1975	NULpcnhrTnWwY4Tpc44hSXO\|YYm=	NEfMTlYyODBizszN	NFnqWnAyPTBibXnu	M2HZe2ROW09?	MX;JcoR2[3Srb36gc4YhVk9icILv[JVkfGmxbjDpckBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiaHHyZo9zcW6pIFXHSnIhVDh3OGKvWFc6OE1ibYX0ZY51	NG\Wbpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[wO\|U6OSd-MkS2NFc2QTF:L3G+
BEAS2B	M3GzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojaOVAh\|ryP	M2X2bFczKGh?	NED4bpNFVVOR	NH3Cb45KSzVyPUGzMlk1KM7:TR?=	NWXNUGFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NFc2QTFpPkK0OlA4PTlzPD;hQi=>
KB	M4\HfGtqdmG\|ZTDBd5NigQ>?	MlfsNVAh\|ryP	MXSxJIg>	NVrYTo53TE2VTx?=	M3HOTGlvcGmkaYTpc44hd2ZiRVfGMZN1cW23bHH0[YQh[XW2b4Doc5NxcG:{eXzheIlwdiCxZjDFS2ZTKHerdHigTWM2OCCxZjCwMlAzPSEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDRzMUGyN{c,OjR2MUGxNlM9N2F-
Calu3	M4Hxd2N6fG:2b4jpZ{BCe3OjeR?=		MoXuO\|IhcA>?	NITkNXNFVVOR	MnzVR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR4FtfTNiY3XscJMh\XiycnXzd4lv\yCKRWKyJJdqfGhiSVO1NEBw\iByLkm5JO69VQ>?	NWPSfFlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVEyOjNpPkK0OFEyOTJ\|PD;hQi=>
A431	NIO5e2pEgXSxdH;4bYMhSXO\|YYm=		M1vRZVczKGh?	Mk\uSG1UVw>?	NV[yS5hIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCneIDy[ZN{cW6pIFXHSnIhf2m2aDDJR\|UxKG:oIECuOVUh\|ryP	NFnYRoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESxNVEzOyd-MkS0NVEyOjN:L3G+
MDCK2	NGnRTGhHfW6ldHnvckBCe3OjeR?=	M3zOd\|EvQCEQvF2=	M37sWlczKGh?	NV3jZnNpTE2VTx?=	MWLJcohq[mm2aX;uJI9nKGi3bXHuJGJEWlBiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJGhw\WOqc4SgN\|M{PDJiYXPjeY12dGG2aX;uJJdqfGhiSVO1NEBw\iB\|LkG5JO69VQ>?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NEKxN{c,OjRzOESyNVM9N2F-
MDCK	NVrDS5JPS3m2b4TvfIlkKEG\|c3H5		MV:3NkBp	MY\EUXNQ	NXu5XYh7T0l3ME2xMlQ2KM7:TR?=	NVfwVHZ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFQzOTNpPkK0NVg1OjF\|PD;hQi=>
BCRP-MDCK2	NGT3T41HfW6ldHnvckBCe3OjeR?=	NEHuV4wyNjhizszN	NF3LTnE4OiCq	MXTEUXNQ	MX\S[YR2[3Srb36gc4YheGyjc33hJI1mdWK{YX7lJIV5eHKnc4Ppc44hd2ZiQlPSVEBmgHC{ZYPzbY5oKHKncH;yeIVzKGenbnWgS2ZR	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF6NEKxN{c,OjRzOESyNVM9N2F-
BCRP-MDCK2	NEjOS\|ZHfW6ldHnvckBCe3OjeR?=	NVHJb49SOS56IN88US=>	NXPhV411PzJiaB?=	M1jmNmROW09?	MV7JcoNz\WG\|ZTDv[kBxdGG\|bXGgcYVu[nKjbnWg[ZhxemW\|c3nvckBw\iCEQ2LQJIV5eHKnc4PpcochemWyb4L0[ZIh\2WwZTDHSnA>	NGqzdIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4OFIyOyd-MkSxPFQzOTN:L3G+
A431	MUPLbY5ie2ViQYPzZZk>	M{\ReFExOCEQvF2=	NVPESFg6OzBibXnu		MUfJcohq[mm2aX;uJI9nKEWJRmKgbY4he2inZDDt[Y1jemGwZTD2[ZNq[2ynczD3bZRpKEmFNUCgc4YhOS5zIN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NESzNkc,OjRyOUS0N\|I9N2F-
HCC827	NX;MUFgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWWxNEDPxE1?	NH3HUVg4OiCq	M1zpO2ROW09?	M3zGU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZNmdnOrdHn2[UBpfW2jbjDIR2M5OjdiY3XscJMhcGG{Yn;ybY5oKEWJRmKgSVc1PiC2bzDBO\|UxKGSnbHX0bY9vKHerdHigTWM2OCCxZjCwMlAxPThzIN88US=>	MkP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNUO2O\|QoRjJ2MEWzOlc1RC:jPh?=
HCC827	NIPN[XpHfW6ldHnvckBCe3OjeR?=	MnTmNE42KM7:TR?=	MVWyJIg>	NXy1cWQ6TE2VTx?=	Ml\hTY5pcWKrdHnvckBw\iClLV3leEBxcG:\|cHjvdplt[XSrb36gbY4h\2WoaYTpcoljNXKnc3nzeIFvfCCqdX3hckBJS0N6MkegZ4VtdHN?	MnP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7OUOzNlgoRjJ\|OUmzN\|I5RC:jPh?=
HCC827	NV7YdYJjU2mwYYPlJGF{e2G7	MWKwMlUh\|ryP	MXKyJIg>	NVXrRZk4TE2VTx?=	NETEPZFKdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hUEOFOEK3JINmdGy\|	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl7M{OyPEc,OjN7OUOzNlg9N2F-
A549	NWjmfZh[TnWwY4Tpc44hSXO\|YYm=	MmHXNUDPxE1?	M4DNRVEhcA>?	NX\tNHM3TE2VTx?=	MkXsR4VtdHWuYYKgeZB1[Wun	NGDwUWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m4PFM2PCd-MkO5PFg{PTR:L3G+
A549	NHfhdVdMcW6jc3WgRZN{[Xl?	NXjCXY93OSEQvF2=	M{DxWFEhcA>?	NH;iS29FVVOR	MULJcohq[mm2aX;uJI9nKEWJRmKgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wN\|k6KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl6OEO1OEc,OjN7OEizOVQ9N2F-
HCC827	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFi1[mM4OiCq		MXvJR\|UxRTBwMEGyJO69VQ>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl5M{G2PEc,OjN7N{OxOlg9N2F-
PC9	MkPhT4lv[XOnIFHzd4F6		M4rrNlIhcA>?	NHu2Um5FVVOR	NWrXPYxGUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wNFg4KM7:TR?=	NIDn[3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{mzNFk6PCd-MkO5N\|A6QTR:L3G+
LoVo	MWPLbY5ie2ViQYPzZZk>		NX\iZZBkOiBiaB?=	MXfEUXNQ	NEWyfo1KdmirYnn0bY9vKG:oIFXHSnIheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkC2NkDPxE1?	M17rcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUOwPVk1Lz5{M{mzNFk6PDxxYU6=
SH-SY5Y	M37C[mN6fG:2b4jpZ{BCe3OjeR?=		NEnpdWs4OiCq		MoDSTWM2OD1zOD6yNUDPxE1?	M3TF[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEexPVA6Lz5{M{i3NVkxQTxxYU6=
A549	NHK4WlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUO3NkBp	NGKyflZFVVOR	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIfpcIQhfHmyZTDFS2ZTN2tvUnHzJIRmeGWwZHXueEBpfW2jbjDBOVQ6KGOnbHzzJJdqfGhiSVO1NEBw\iB2Lk[yOkDPxE1?	NVTaclQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI{OThpPkKzO\|kzOzF6PD;hQi=>
16HBE	NXH5TFZUTnWwY4Tpc44hSXO\|YYm=	MW[xNFAh\|ryP	MUixOVAhdWmw	NHexZ5RFVVOR	MWDJcoR2[3Srb36gc4Yhdmm2cnnjJI95cWSnIIDyc4R2[3Srb36gbY4hcHWvYX6gNVZJSkViY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVi=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkOxPEc,OjN5OUKzNVg9N2F-
16HBE	MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Ml73O\|IhcA>?	M3\mb2ROW09?	NUOydHI{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjCxOmhDTSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCHR1\SJJdqfGhiSVO1NEBw\iBzLk[wNUDPxE1?	NGjTUnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlMyQCd-MkO3PVI{OTh:L3G+
NCI-H1975	NVjR[pJYS3m2b4TvfIlkKEG\|c3H5	NVH6TGpZOTBizszN	M3Pq[\|czKGh?	NFPW[GVFVVOR	M2jxcWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGenZnn0bY5q[i2{ZYPpd5RidnRiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDZwOUG3JO69VQ>?	MlfCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nki0OFEoRjJ\|Nk[4OFQyRC:jPh?=
16HBE14o-	NYHneGRRS3m2b4TvfIlkKEG\|c3H5	MkPCNVAh\|ryP	NUXZT3liPzJiaB?=	MoT2SG1UVw>?	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjCxOmhDTTF2bz2gZ4VtdHNiaHHyZo9zcW6pIIfpcIQhfHmyZTDFS2ZTKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAyOi55MTFOwG0>	M{OwXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Nk[4OFQyLz5{M{[2PFQ1OTxxYU6=
Sf9	MWHLbY5ie2ViQYPzZZk>		NX:4eFFZOSCq	M3TaOGROW09?	MlTrTY5pcWKrdHnvckBw\iCqdX3hckBIW1RvdHHn[4VlKEWJRmKgUFg{PFJibYX0ZY51KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNE4xOTVizszN	M2nJUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkGxOlkyLz5{M{[xNVY6OTxxYU6=
PC9	NHrBVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3z4cFExKM7:Zz;tUC=>	NXXXPVVKPzJiaB?=		MYXJR\|UxRTBwMEG0JO69VQ>?	M{\6NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVY5Lz5{M{GxOlE3QDxxYU6=
HCC827	M2D0Z2N6fG:2b4jpZ{BCe3OjeR?=	M{eyeFExKM7:Zz;tUC=>	MmLnO\|IhcA>?		MXXJR\|UxRTBwMECxOUDPxE1?	NHTEZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{GxOlE3QCd-MkOxNVYyPjh:L3G+
FADU	MlHUR5l1d3SxeHnjJGF{e2G7	M4X5clExKM7:Zz;tUC=>	NUT4SJhuPzJiaB?=		NI\VU2tKSzVyPUCuNFUh\|ryP	NWDaPZRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNVYyPjhpPkKzNVE3OTZ6PD;hQi=>
Calu3	MmfFR5l1d3SxeHnjJGF{e2G7	Mnv3NVAh\|rypL33M	NHr2bIo4OiCq		MUjJR\|UxRTFwNjFOwG0>	M3exNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUG2NVY5Lz5{M{GxOlE3QDxxYU6=
A498	NITtZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4mzNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDlfJBz\XO\|aX7nJGVITlJiYX7kJHNTSyC5aYToJGlEPTBib3[gPE43KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhzOEi0PEc,OjJ6MUi4OFg9N2F-
SGC7901	NIDwZ5BEgXSxdH;4bYMhSXO\|YYm=		NUHOb3hwPzJiaB?=		NH3McVVKSzVyPUGwMlI3KM7:TR?=	NWnjNG9XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3Nlc1PDlpPkKyO\|I4PDR7PD;hQi=>
HT-29	Mk\5R5l1d3SxeHnjJGF{e2G7		NHruPJY4OiCq		NX2zOFFoUUN3ME2zMlM3KM7:TR?=	M4ruVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K3OFQ6Lz5{MkeyO\|Q1QTxxYU6=
H460	M2fzfWN6fG:2b4jpZ{BCe3OjeR?=		M{T0bFczKGh?		MYXJR\|UxRTVwNUmg{txO	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{N{S0PUc,OjJ5Mke0OFk9N2F-
A431	NV7iUnAzU2mwYYPlJGF{e2G7	Ml;RNVAxKM7:TR?=	NV:1[4RROzBibXnu		M4nGfGlvcGmkaYTpc44hd2ZiRVfGVkBl\XKrdnXkJIZzd21iaIXtZY4hSTR\|MTDj[YxtKG2nbXLyZY5mKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YheG:ueT3HcJUuXHm{IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNU4xQCEQvF2=	MmHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4OUi3PFIoRjJ{Nkm4O\|gzRC:jPh?=
HCC827	M2P4PGtqdmG\|ZTDBd5NigQ>?	MmS0NE4yOjVizszN	NEmxOYYzPCCq	MnK0SG1UVw>?	NHzGUo1KdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=	MoXyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{mzOFIoRjJ{M{O5N\|QzRC:jPh?=
HCC827	NHHRW49McW6jc3WgRZN{[Xl?	NHHXdlgxNjF{NTFOwG0>	MYWyOEBp	MUHEUXNQ	NEX0cZVKdmirYnn0bY9vKG:oIFXHSnIh\GWuIFW3OFYuSTd3MDDteZRidnRvbXXkbYF1\WRiRYLrJJBpd3OyaH;yfYxifGmxbh?=	M3XsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{O5N\|QzLz5{MkOzPVM1OjxxYU6=
HCC827	MlXoT4lv[XOnIFHzd4F6	NVG4[WsyOC5zMkWg{txO	NUDMTpZ{OjRiaB?=	MV\EUXNQ	Ml;xTY5pcWKrdHnvckBw\iCHR1\SJIRmdCCHN{S2MWE4PTBibYX0ZY51KFlzME[4JIF2fG:yaH;zdIhwenmuYYTpc44>	Ml;vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|M{mzOFIoRjJ{M{O5N\|QzRC:jPh?=
MCF7	M37SOGN6fG:2b4jpZ{BCe3OjeR?=	M4DrOVExKM7:TR?=	M3ixe\|Q5KGh?		MXzDfZRwfG:6aXPpeJkh[WejaX7zeEB{\XK3bT3zeIFzfmWmIHj1cYFvKE2FRkegZ4VtdHNib4\ldk1mgHC{ZYPzbY5oKEW{YlKyJINmdGy\|	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF\|OEOwPEc,OjJzM{izNFg9N2F-
BT474	NWDKSYtLS3m2b4TvfIlkKEG\|c3H5	NEf4OnEyOCEQvF2=	NF;adG41QCCq		M1zzWGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KHOncoXtMZN1[XK4ZXSgbJVu[W5iQmS0O\|Qh[2WubIO=	M{nmblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO4N\|A5Lz5{MkGzPFMxQDxxYU6=
MCF7	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXyVHA6OTBywrFOwIcwdUx?	M4L3dVQ5KGh?	NULLe3J3TE2VTx?=	NUO1VVVDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJI93\XKneIDy[ZN{cW6pIFXHSnIh\2WwZTD3bZRpKEmFNUCgc4YhOTJwMEWg{txO	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFzOUGzNEc,OjJzMUmxN\|A9N2F-
A431	MoLDT4lv[XOnIFHzd4F6		NF\VOZAzKGh?	M4XwR2ROW09?	MYnJcohq[mm2aX;uJI9nKEWJRmKgdIhwe3Cqb4L5cIF1cW:wIHnuJGVITi2\|dHnteYxifGWmIHj1cYFvKEF2M{Gge4l1cCCLQ{WwJI9nKDBwMECxJO69VQ>?	NXrOUWRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxNFEyOzJpPkKyNVAyOTN{PD;hQi=>
NCI-H292	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MU[3NkBp	NEHFNo9FVVOR	NEiwRlBKSzVyPUCuNFIh\|ryP	M2P4dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUG2OFM{Lz5{MUmxOlQ{OzxxYU6=
NCI-H1993	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NH7lS\|E4OiCq	MXvEUXNQ	NITLNWtKSzVyPUCuNUDPxE1?	M2[4OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUG2OFM{Lz5{MUmxOlQ{OzxxYU6=
Plasmodium falciparum					NUXVN\|ZTeUiWUzDwdo9ncWyrbneg[o9zKGmwaHnibZRwenNib3[gVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36=	NGq2TVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixO\|A1PSd-MkG4NVcxPDV:L3G+
MDA-MB-468	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxNFAh\|ryP	NXrCUoFwPDhiaB?=	MnrySG1UVw>?	M3zHV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5	M1zEfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEK5OlMzLz5{MUSyPVY{OjxxYU6=
PC3	NYjPSmhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmK0NVAh\|ryP	MmToO\|IhcA>?	NYXhUVM2TE2VTx?=	NFHQVVdKSzVyPUeuOEDPxE1?	NFHGb2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO1N\|U1Pid-MkGzOVM2PDZ:L3G+
PC9	Mlq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjxUm51SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBoem:5dHitdoV{cXO2YX70JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiRUe0On9CPzVyL2S3PVBOKG23dHHueEB4cXSqIFXDOVAhd2ZiNzFOwG0>	MmDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MEi4NFIoRjJzMkC4PFAzRC:jPh?=
PC9	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3rRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDFS2ZTNWSnZnnjbYVvfCCqdX3hckBRSzliY3XscJMhf2m2aDDFR\|UxKG:oIECuNFE4KM7:TR?=	NUD5U2NGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNFg5ODJpPkKxNlA5QDB{PD;hQi=>
PANC1	MlTmR5l1d3SxeHnjJGF{e2G7		M{SzWFUh\A>?	MoC1SG1UVw>?	MVzJR\|UxRTRyLkSyJO69VQ>?	Ml\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
MIAPaCa2	NHjMT45EgXSxdH;4bYMhSXO\|YYm=		NETKVFU2KGR?	MV\EUXNQ	MoDzTWM2OD13MD62NkDPxE1?	M3ziNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
DU145	MV3DfZRwfG:6aXOgRZN{[Xl?		MX61JIQ>	MWHEUXNQ	M3nNT2lEPTB;NEKuNVch\|ryP	MlW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2Nk[1OVUoRjJyNE[2OVU2RC:jPh?=
SMMC7721	NXXWWolkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXm0PEBp		MoLwTWM2OD1\|Mz6xNkDPxE1?	NUX1d2p1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFQ2OzdpPkKwN\|A1PTN5PD;hQi=>
A375	MofoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MoXhOFghcA>?		M{f2b2lEPTB;MkCuOVUh\|ryP	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|MES1N\|coRjJyM{C0OVM4RC:jPh?=
NCI-H1975	NHm2dYJHfW6ldHnvckBCe3OjeR?=	NE\KO3A2KM7:TR?=	MoDvOFghcA>?		MoDSTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCjc4Pld5Nm\CCjczDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UuOw>?	MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUG2O\|AoRjJyMUWxOlcxRC:jPh?=
NCI-H1975	NIL3doJHfW6ldHnvckBCe3OjeR?=	NHn6dmcyOCEQvF2=			MmnqTY5pcWKrdHnvckBw\iCHUlLCNkBifXSxcHjvd5Bpd3K7bHH0bY9v	NYHnR4hQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOVE3PzBpPkKwNVUyPjdyPD;hQi=>
NCI-H1975	MoLLT4lv[XOnIFHzd4F6	MVGxNEDPxE1?			M{fZT2lvcGmkaYTpc44hd2ZiRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9v	M2DX[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUWxOlcxLz5{MEG1NVY4ODxxYU6=
NCI-H1975	M{DpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TLWlUh\|ryP	MV23NkBp		MmS4TWM2OD16LkK2JO69VQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3MU[3NEc,OjBzNUG2O\|A9N2F-
Sf9	MYPLbY5ie2ViQYPzZZk>		MnTwNVAhdWmw	MojoSG1UVw>?	M4XI[WlvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\WOncITvdkBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlA{OyEQvF2=	NXXlTnF7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVY1OjVpPkKwNFU3PDJ3PD;hQi=>
A431	NETiemdMcW6jc3WgRZN{[Xl?	NEWwUHYyODBizszN	M2jVTlExKG2rbh?=		MYjQdo9td26pZXSgbY5pcWKrdH;yfUBi[3Srdnn0fUBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7Nkm0OlUoRjF7OU[5OFY2RC:jPh?=
A431	NYi2c4dpU2mwYYPlJGF{e2G7	NY\IUmZJOC5zIN88US=>	NV\OfXFZOSCq		Ml\qTY5pcWKrdHnvckBw\iCHR1[tbY5lfWOnZDDFS2ZTKHCqb4PwbI9zgWyjdHnvci=>	NYDFVlBqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
A431	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;BUG1XOTBizszN	NH;oRo84OiCq		NILkfWFIUTVyPUCuOVE1KM7:TR?=	NYPS[YRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
MCF7 MX	MnTCSpVv[3Srb36gRZN{[Xl?		NVz3flJROzBibXnu		NVzPNm9tUW6qaXLpeIlwdiCxZjDCR3JRKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4yKM7:TR?=	MkH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7M{K5OlAoRjF7OUOyPVYxRC:jPh?=
NIH3T3	NGT4RmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlrnO\|IhcA>?		MnjMS5Jwf3SqIHnubIljcXSrb36gc4YhdW:3c3WgUmlJNzOWMzDj[YxteyCneIDy[ZN{cW6pIHXyRlIh\2WwZTD3bZRpKEmFNUCgc4YhOC53NDFOwG0>	M4TNfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Nk[1N\|c4Lz5zOU[2OVM4PzxxYU6=
BA/F3	NIfJRnBEgXSxdH;4bYMhSXO\|YYm=		M2rNUVczKGh?		M3HoSGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6UjDteZRidnRid3n0bEBKSzVyIH;mJFAvODFyODFOwG0>	NWf0O4MxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyN\|kzOjlpPkG5NlM6OjJ7PD;hQi=>
HN5	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MV[3NkBp		MlfpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTkWgZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEWFNUCgc4YhOC5yMTFOwG0>	NILMbnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCyPFQzPCd-MUmwNlg1OjR:L3G+
BT474	NF6zdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIXYUZU4OiCq		Mm\ZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCEVES3OEBk\WyuczDveoVz\XiycnXzd4lv\yCHUlLiNkB4cXSqIFXDOVAhd2ZiMD6zJO69VQ>?	NG\HW3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCyPFQzPCd-MUmwNlg1OjR:L3G+
MCF7	MnuzR5l1d3SxeHnjJGF{e2G7	NXWyNY5SPTBizszN	NH\nc\|M4OiCq		NEnpS2tKSzVyPUGyMlA2KM7:TR?=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDd5MUixPUc,OTh5N{G4NVk9N2F-
MOLT4	MonJR5l1d3SxeHnjJGF{e2G7		MkT6PVYhcA>?	Mn6xSG1UVw>?	M2jvbmlEPTB;MUWuNFIh\|ryP	NHL3UpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|gxPyd-MUizNVM5ODd:L3G+
MDA-MB-231	MmO1R5l1d3SxeHnjJGF{e2G7		MXK5OkBp	NFjjT3lFVVOR	NHHrbZNKSzVyPUO2MlYyKM7:TR?=	NIKySYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|gxPyd-MUizNVM5ODd:L3G+
K562	MmfQR5l1d3SxeHnjJGF{e2G7		NWLZbI46QTZiaB?=	MoDCSG1UVw>?	MnjrTWM2OD17LkO2JO69VQ>?	NFKxOpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOxN\|gxPyd-MUizNVM5ODd:L3G+
A549	NV3nVIdRS3m2b4TvfIlkKEG\|c3H5		NGHl[mc6PiCq	MmLXSG1UVw>?	NHvoemRKSzVyPUGzMlU6KM7:TR?=	M1PyR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{GzPFA4Lz5zOEOxN\|gxPzxxYU6=
COS7	MUnGeY5kfGmxbjDBd5NigQ>?	MY[5OkDPxE1?			NFPVO2pKdmirYnn0bY9vKG:oIHj1cYFvKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5Nm\A>?	NWezS2w4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
NIH3T3	M1vEemZ2dmO2aX;uJGF{e2G7	MX2wMlIh\|ryP	NYnLPJlyOiCq	NVzIZYllTE2VTx?=	MYnJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODF2NDFOwG0>	M4SzdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEiwNlg1Lz5zNkS4NFI5PDxxYU6=
KB	NVXCcHRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvUfmJKSzVyPUCuNFU1KM7:TR?=	M3rJd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NUG2OFc{Lz5zNkWxOlQ4OzxxYU6=
GAK	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fCSmlEPTB;MkGuOFk6KM7:TR?=	NVTHRVZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3PVU4PjdpPkK5O\|k2PzZ5PD;hQi=>
SK-N-AS	M3ftO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoizTWM2OD1{MT61OlE6KM7:TR?=	MnvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4OUGzOFkoRjF7NkmxN\|Q6RC:jPh?=
OE33	NGrS[2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJzLk[wOFYh\|ryP	NIrVfmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
YKG-1	NV7RW\|VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHn5WnBKSzVyPUKxMlY2PDVizszN	NVPxWFR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OFQyOTlpPkKyPVQ1OTF7PD;hQi=>
CAL-85	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTJzLkmzNFUh\|ryP	M3zyTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOxN\|U6Lz5{NE[zNVM2QTxxYU6=
NCI-H2347	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jxdGlEPTB;MkGuPVQzQCEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{MUe5NEc,Ojh{MkG3PVA9N2F-
PANC-08-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJ{LkCxNVkh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{MUe5NEc,Ojh{MkG3PVA9N2F-
SK-N-FI	NVn5N5RIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjmTWM2OD1{Mj6zNFc1KM7:TR?=	MmC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
NEC8	NGroZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkOxTWM2OD1{Mj61NFc5KM7:TR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl2NEGxPUc,OjJ7NESxNVk9N2F-
AN3-CA	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTJ{Lk[wPFQh\|ryP	NVfmR4cxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5OFQyOTlpPkKyPVQ1OTF7PD;hQi=>
HuO9	M1jRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nwNGlEPTB;MkKuO\|M6PiEQvF2=	Ml3KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyM{KzN\|EoRjJ5MEOyN\|MyRC:jPh?=
COLO-800	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTJ{Lke2OVMh\|ryP	NWTLR3FmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzOFE{PTZpPkK0N\|QyOzV4PD;hQi=>
HT-29	NF\FUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\vTmpYUUN3ME2yNk45QDJ\|IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
OC-314	NF3qS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoOxTWM2OD1{Mj64PFQ2KM7:TR?=	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5M{e0NEc,OjB6N{O3OFA9N2F-
G-401	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jq[WlEPTB;MkOuNFQ3OiEQvF2=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
Saos-2	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rYbmlEPTB;MkOuOVE5OiEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5MUm5PEc,OjR2N{G5PVg9N2F-
UACC-62	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTJ\|LkW4N\|Mh\|ryP	M1;1b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkmxN\|Q6Lz5zOU[5NVM1QTxxYU6=
D-247MG	NHniV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJ\|Lke5N\|kh\|ryP	MmPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
COLO-741	NVn1d3VQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUPGNpAzUUN3ME2yN{46PTZ3IN88US=>	MnW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OEC1OVQoRjJyNUiwOVU1RC:jPh?=
ES3	NGnsfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfBTWM2OD1{ND6wNFI{KM7:TR?=	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{MUe5NEc,Ojh{MkG3PVA9N2F-
LNCaP-Clone-FGC	M3HLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX4[296UUN3ME2yOE4xOjFzIN88US=>	MkfUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{MkG3PVAoRjJ6MkKxO\|kxRC:jPh?=
SW1710	M1:2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLrTWM2OD1{ND6xOVA3KM7:TR?=	MnnIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyOUS5PVIoRjJ\|MEm0PVkzRC:jPh?=
LU-99A	NWrHNHpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC0TWM2OD1{ND6xPFQyKM7:TR?=	M2DNWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCyOFY1Lz5zN{[wNlQ3PDxxYU6=
HOP-92	MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfUTWM2OD1{ND63NlUh\|ryP	NWnGfoRqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O\|E6QThpPkK0OFcyQTl6PD;hQi=>
LS-123	NEfrPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofCTWM2OD1{ND65OlE1KM7:TR?=	MoDnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NEKxOFYoRjJ{M{SyNVQ3RC:jPh?=
T84	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjueVNKSzVyPUK0Mlk4PjVizszN	NHnSO4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOyPFY2Pid-MkmzNlg3PTZ:L3G+
HCT-116	M1[1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7uN\|lKSzVyPUK1MlQyQDZizszN	NW\1SlN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0O\|EyOTlpPkK5OFcyOTF7PD;hQi=>
M14	NGWwUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnW0TWM2OD1{NT60OFQ4KM7:TR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
OCUB-M	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILXeGlKSzVyPUK1MlQ1PTZizszN	NYfuW\|B3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
MKN45	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDVTWM2OD1{NT62N\|E2KM7:TR?=	NYXHZphFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlU5PzVpPkK2NFI2QDd3PD;hQi=>
LCLC-97TM1	NGnxcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXMbmVFUUN3ME2yOU44Ojh3IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV6OEK4NUc,OTh3OEiyPFE9N2F-
RVH-421	NV\UN3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3naSGlEPTB;MkWuPFE3OSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5M{e0NEc,OjB6N{O3OFA9N2F-
NKS-81-FD	NY\ISHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1G0RmlEPTB;MkWuPVAzOSEQvF2=	M3n5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkKxO\|kxLz5{OEKyNVc6ODxxYU6=
NCI-H596	MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\DbXdKSzVyPUK2MlA1QDdizszN	NVHS[GU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMzQTZpPkK1O\|A{Ojl4PD;hQi=>
GB-1	NFTJbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLTWFNTUUN3ME2yOk4yQDd7IN88US=>	NHKwNHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNlQ3PCd-MUe2NFI1PjR:L3G+
ZR-75-30	NWnV[ZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJ4LkKyPVch\|ryP	MkS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
U-2-OS	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo\TTWM2OD1{Nj6zO\|U4KM7:TR?=	NX3OXHBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOFIyPDZpPkKyN\|QzOTR4PD;hQi=>
HuP-T3	NWnK[pZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTJ4Lk[xNFIh\|ryP	NEjI[4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
MOLT-16	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf1TnZkUUN3ME2yOk43OTZ4IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZyMkS2OEc,OTd4MEK0OlQ9N2F-
U-87-MG	NFywU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLBWJBHUUN3ME2yOk44PDN6IN88US=>	Mme2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
8505C	Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmP4TWM2OD1{Nj65NVI3KM7:TR?=	NF3NU3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW4PFI5OSd-MUi1PFgzQDF:L3G+
SK-MEL-3	NXzCWohPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3[wfmlEPTB;Mk[uPVgzQCEQvF2=	M4mxVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
COLO-824	M4L5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P5[WlEPTB;MkeuNlE6PSEQvF2=	Mn;CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4M{GzOVkoRjJ2NkOxN\|U6RC:jPh?=
EW-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYP2R4pwUUN3ME2yO{4{PTV2IN88US=>	NE\rO2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[1OlIxOid-Mkm2OVYzODJ:L3G+
UACC-257	NU\PPHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUTLWVZYUUN3ME2yO{4{QDB2IN88US=>	NXTLNWZSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlE4QTBpPkK4NlIyPzlyPD;hQi=>
Hs-578-T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\oZYtKSzVyPUK3MlUzQTlizszN	NGfXdYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
UACC-893	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXQPHFZUUN3ME2yO{43PjNzIN88US=>	NETF[YE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO0NlE1Pid-MkKzOFIyPDZ:L3G+
MHH-NB-11	M3fwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\yZmlEPTB;MkeuPFAxPyEQvF2=	NWXpUlJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4O\|M4PDBpPkKwPFc{PzRyPD;hQi=>
KYSE-410	NUT0UXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIX4[FVKSzVyPUK4MlI4PzlizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
SF126	NYDnZ2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHi0UoFKSzVyPUK4Mlc1OzVizszN	MoTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
HT-144	M1rBS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIf4cJVKSzVyPUK5MlM{PjJizszN	M4G3NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{M{SyNVQ3Lz5{MkO0NlE1PjxxYU6=
SW1573	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInTNplKSzVyPUK5MlM2ODlizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{NUi3OUc,OjZyMkW4O\|U9N2F-
SW620	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfNTWM2OD1{OT6zOlQyKM7:TR?=	NG\1SFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEC3OVU6Oid-MkiwO\|U2QTJ:L3G+
SCH	NFjYT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTJ7Lki4N\|Eh\|ryP	M4rPclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEezO\|QxLz5{MEi3N\|c1ODxxYU6=
EW-22	NYrwS5hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrRUGVKSzVyPUOwMlE6PjlizszN	NXHXUWh1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFMzQTZpPkK1O\|A{Ojl4PD;hQi=>
H4	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTNyLkS2OVQh\|ryP	M2Dhb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEK1PFc2Lz5{NkCyOVg4PTxxYU6=
CAS-1	M3rrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLFOWdKSzVyPUOwMlc5PTlizszN	MoDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{G5PVgoRjJ2NEexPVk5RC:jPh?=
MG-63	MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfuXmU2UUN3ME2zNE45PDd6IN88US=>	NV;kZppuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
MDA-MB-415	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2ezfGlEPTB;M{GuNVc2OyEQvF2=	Ml:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
NCI-H1395	NV7ScpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfS[JJKSzVyPUOxMlI{OjhizszN	MnLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
Ca-Ski	MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXhTWM2OD1\|MT6zNVc4KM7:TR?=	NX7qVnZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
BxPC-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTiTWM2OD1\|MT6zO\|I6KM7:TR?=	NHzFdVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNVM2QSd-MkS2N\|E{PTl:L3G+
A3-KAW	NITDOm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILFdIdKSzVyPUOxMlQ1PzFizszN	M{Hoc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkCyOFY1Lz5zN{[wNlQ3PDxxYU6=
T-24	NU\vUW5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TDeWlEPTB;M{GuO\|M3OiEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV6MEW1OEc,OjB3OEC1OVQ9N2F-
NCI-H2029	MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDhRYdKSzVyPUOxMlc4PjVizszN	NGLtfWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES3NVk6QCd-MkS0O\|E6QTh:L3G+
YAPC	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PTb2lEPTB;M{KuNFQxPyEQvF2=	M{\JNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{GxNFU1Lz5{MUexNVA2PDxxYU6=
SK-MEL-2	NVLmVJhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTN{LkC1NkDPxE1?	M4TKS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{[yOFc1Lz5zOUO2NlQ4PDxxYU6=
LS-513	NY[x[FZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M364VGlEPTB;M{KuNVE5PyEQvF2=	MkjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
AsPC-1	NEn0Sm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHJUmx6UUN3ME2zNk4{PjB3IN88US=>	NEnjelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GwNVY4PCd-MUexNFE3PzR:L3G+
KYSE-150	NF\WSWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN{LkO3O\|Mh\|ryP	M33SRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkOwNVMyLz5{M{KzNFE{OTxxYU6=
NCI-H520	MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7xTWM2OD1\|Mj60OFgzKM7:TR?=	NXPSZVJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
JEG-3	NGq3WJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEf4V5JKSzVyPUOzMlA6PzFizszN	NGrCeWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KzNFE{OSd-MkOyN\|AyOzF:L3G+
GMS-10	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2n4WWlEPTB;M{OuN\|AxPCEQvF2=	NFuySW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUexNVA2PCd-MkG3NVExPTR:L3G+
HT-1080	NYOwWnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEfO[JRKSzVyPUOzMlM6KM7:TR?=	NFLx[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG5OVQ3Pid-MkSxPVU1PjZ:L3G+
NCI-H1651	NEjHS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3SzRWlEPTB;M{OuN\|k3KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTN4MkS3OEc,OTl\|NkK0O\|Q9N2F-
NCI-H2122	M{HZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTN\|LkW1O\|Qh\|ryP	M1W5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEezO\|QxLz5{MEi3N\|c1ODxxYU6=
ES5	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTN\|LkeyPVIh\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ3NkKwNkc,Ojl4NU[yNFI9N2F-
8305C	NGWzdlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnTTWM2OD1\|Mz65PVM4KM7:TR?=	NFzob3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO2NlQ4PCd-MUmzOlI1PzR:L3G+
KM12	NWjiPGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDobpNKSzVyPUO0MlA1PzhizszN	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ\|MEGzNUc,OjN{M{CxN\|E9N2F-
HCT-15	MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjpb\|RzUUN3ME2zOE4yOjdizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4OEiyOEc,OjN7Nki4NlQ9N2F-
OVCAR-5	M3fhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTw[WZ6UUN3ME2zOE4zOTh{IN88US=>	NH7WPXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2O\|U6OCd-MkS4Olc2QTB:L3G+
NCI-H2291	M1HV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLnTWM2OD1\|ND6yOFczKM7:TR?=	NXqzXVV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyN\|AyOzFpPkKzNlMxOTNzPD;hQi=>
CP50-MEL-B	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M12zVWlEPTB;M{SuOlU6OiEQvF2=	M2\Oc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC1O\|IzLz5{NUGwOVczOjxxYU6=
C-33-A	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTN2Lk[4OVch\|ryP	MkG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7Nk[5OVAoRjJ5OU[2PVUxRC:jPh?=
NCI-H2452	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojCTWM2OD1\|ND63PFgzKM7:TR?=	MlzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
MDA-MB-157	NIfKcm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DYNGlEPTB;M{SuPFE6OyEQvF2=	NEn4PVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUO2NlQ4PCd-MUmzOlI1PzR:L3G+
LN-405	M1nIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGm4enlKSzVyPUO1MlQ{ODhizszN	NHHlZmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi3N\|c1OCd-MkC4O\|M4PDB:L3G+
MDA-MB-231	NH;GUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYKzd4VXUUN3ME2zOU42ODV2IN88US=>	NWW3U\|dFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOlAyODRpPkKzN\|YxOTB2PD;hQi=>
EW-24	M3TuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHG5[2FKSzVyPUO1MlY{OzVizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4OEiyOEc,OjN7Nki4NlQ9N2F-
MKN28	M3zPfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK3UmpKSzVyPUO1MlgzOzZizszN	MmX6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|NkK0O\|QoRjF7M{[yOFc1RC:jPh?=
KINGS-1	Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjtZVd7UUN3ME2zOU45PDN2IN88US=>	NEL3c2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOyPFY2Pid-MkmzNlg3PTZ:L3G+
LC-2-ad	MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTN4Lk[5PUDPxE1?	M3;YVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CzNlk3Lz5{NUewN\|I6PjxxYU6=
IGR-1	NVjjbYpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fMWWlEPTB;M{[uO\|A4PSEQvF2=	NYDjUWVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0N\|Y6QTRpPkK0OFM3QTl2PD;hQi=>
SW626	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTN5LkC0NVch\|ryP	NX63Wmp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK1NVI6ODhpPkKyOVEzQTB6PD;hQi=>
ONS-76	MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT4TWM2OD1\|Nz6xN\|A6KM7:TR?=	Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7Nki4NlQoRjJ\|OU[4PFI1RC:jPh?=
T98G	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUG2OXc1UUN3ME2zO{45PjN3IN88US=>	Mmj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5MUGwOVQoRjJzN{GxNFU1RC:jPh?=
NB14	Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXZV4RKSzVyPUO4MlQ2PDRizszN	MnPCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2M{[5PVQoRjJ2NEO2PVk1RC:jPh?=
D-423MG	M{foUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPj[203UUN3ME2zPE41QDZ7IN88US=>	M2T3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{[yOFc1Lz5zOUO2NlQ4PDxxYU6=
NCI-H510A	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnv1TWM2OD1\|OD62OFUyKM7:TR?=	NUOzNlFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PVUxQDFpPkK4OFk2ODhzPD;hQi=>
NMC-G1	Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUj3UWN{UUN3ME2zPE44OjJ{IN88US=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzMUC1OEc,OjF5MUGwOVQ9N2F-
SW948	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;rTWM2OD1\|OD64PVQ6KM7:TR?=	MoH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|NEGzOVYoRjJ2M{SxN\|U3RC:jPh?=
MFM-223	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnHSWV[UUN3ME2zPE46PDNzIN88US=>	MmHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd2MUm2NFQoRjF5NEG5OlA1RC:jPh?=
PAN1	NEjuenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljtTWM2OD1\|OD65PVE6KM7:TR?=	NFHxZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxNlkxQCd-MkK1NVI6ODh:L3G+
MZ7-mel	M1vVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTN7LkGxPVkh\|ryP	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB5NUW5Nkc,OjhyN{W1PVI9N2F-
COLO-679	M1GzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTN7Lkm3NFgh\|ryP	NV7GXpBDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3NVExPTRpPkKxO\|EyODV2PD;hQi=>
SW872	NIjvS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTRyLkKwN\|Eh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MUO1PUc,OjR4M{GzOVk9N2F-
HT-1197	M3O0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rrdWlEPTB;NECuNlg3QSEQvF2=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNkc,Ojd\|NEmzN\|I9N2F-
ES6	NWDaSpEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTRyLkS1OVIh\|ryP	NV2ySG53RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUixPFY3ODRpPkG4NVg3PjB2PD;hQi=>
SNU-387	M4DFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTRyLkiyN\|gh\|ryP	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzOU[wOEc,OTd2MUm2NFQ9N2F-
T47D	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnPYTWM2OD12MT6wNVkzKM7:TR?=	NVXyZXZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUixPFY3ODRpPkG4NVg3PjB2PD;hQi=>
G-402	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mo[1TWM2OD12MT6wPFA6KM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OU[yOkc,OjN2OEm2NlY9N2F-
MZ1-PC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFL5SXBKSzVyPUSxMlgyKM7:TR?=	NIXiTGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[wNlQ3PCd-MUe2NFI1PjR:L3G+
SW1417	NHPqfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDETWM2OD12Mj6zNFMh\|ryP	MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4MEK0OlQoRjF5NkCyOFY1RC:jPh?=
RERF-LC-MS	MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWrKUYVFUUN3ME20Nk42ODh5IN88US=>	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3N{[2N\|MoRjJ6NUe2OlM{RC:jPh?=
SF539	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TDdmlEPTB;NEKuOVUzQSEQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR6OU[yOkc,OjN2OEm2NlY9N2F-
ESS-1	NHvHe\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK0OmNKSzVyPUSzMlU2PThizszN	NGnFVXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW3OlY{Oyd-Mki1O\|Y3OzN:L3G+
RO82-W-1	MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX35TFBPUUN3ME20N{43OTV\|IN88US=>	NHnLT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW3OlY{Oyd-Mki1O\|Y3OzN:L3G+
S-117	NGD5NVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHW5VYhKSzVyPUSzMlY6PThizszN	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjVzMkmwPEc,OjJ3MUK5NFg9N2F-
SW756	M4fYbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfuUG5xUUN3ME20N{45OjR{IN88US=>	NYfZNoZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
CP66-MEL	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXoTWM2OD12NT63NVQ{KM7:TR?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
H-EMC-SS	NHm5bYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTR3Lke2PVMh\|ryP	NWrPcph6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
NCI-H2052	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PpemlEPTB;NEWuPVAzPyEQvF2=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly5N\|kwLz6VQV7HSXI9N2F-
SW684	M2jqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTR5LkCwPFEh\|ryP	NXvMeYZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
HCC1569	Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D6b2lEPTB;NEeuNVY2QCEQvF2=	NV\UcXpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
KGN	M1WwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIewdXlKSzVyPUS3MlM{OTFizszN	NUDp[4xqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQTN7Lze+V2FPT0WUPD;hQi=>
LCLC-103H	M1THS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYfaUlR5UUN3ME20O{41PDB2IN88US=>	NFXlVYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw6OzlxJ{7TRW5ITVJ:L3G+
SW780	NVez[FFlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTR5Lk[zOVEh\|ryP	M{K2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=
NCI-H1703	MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4XaSmlEPTB;NEiuN\|M2OiEQvF2=	MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPVM6Nyd-U1HOS2VTRC:jPh?=
HCC1395	M1TLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{j2S2lEPTB;NEiuO\|Q{OiEQvF2=	M3mzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFk{QS9pPmPBUmdGWjxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-EGFR / phospho-ERK / phospho-SRC / phospho-AKT; PubMed: 22586683 Cancer Discov Effect of overexpressing CRKL on phosphorylation levels of EGFR, ERK, AKT and SRC in response to gefitinib. HCC827 cells expressing a control vector or CRKL were exposed to gefitinib at indicated concentrations for 6 h and cell lysates were collected for immunoblotting with indicated specific antibodies. Cyclin D1/ p16 / p27 / pRb; PubMed: 18559346 J Biol Chem levels of phosphorylated and total EGFR, IGF-1R, Akt, ERK1/2, and Rb and levels of cyclin D1, p27, p16, and actin following 6- or 16-h treatment of A431 cells with combinations of 1 or 3 μm gefitinib and 3 μm NVP-ADW742. Data are representative of two independent experiments. uc-caspase-9 / c-caspase-9 / uc-caspase-3 / c-caspase-3 / uc-PARP / PARP; PubMed: 23102728 Mol Oncol Apoptosis resulting from combined treatment with gefitinib and an MEK inhibitor. (A) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/wt and PC‐9/gef B4 cells. (B) Apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/wt and PC‐9/gef B4 cells. (C) apoptosis relating protein induced by gefitinib and/or AZD6244 in PC‐9/gefE3 and PC‐9/gefE7 cells. (D) apoptosis relating protein induced by gefitinib and/or CI‐1040 in PC‐9/gefE3 and PC‐9/gefE7 cells. PPAR-γ; PubMed: 23409107 PLoS One Fold increase relative to control was determined after normalization with β-actin as external loading control.	22586683 18559346 23102728 23409107
Immunofluorescence	EGFR / LC3; PubMed: 31196210 J Exp Clin Cancer Res H157 and H1299 cells were treated with gefitinib, or curcumin alone, or gefitinib plus curcumin at indicated concentration for 48 h and then were fixed with methanol, immunostained with anti-EGFR (green), anti-LC3 (red), and DAPI (blue), and analyzed by confocal microscopy to determine the intracellular locations of EGFR and LC3. PPAR-γ; PubMed: 23409107 PLoS One Upregulation and nuclear accumulation of PPARγ following treatment with gefitinib (24 hs). p-EGFR / β-catenin; PubMed: 23461856 FEBS J In untreated CNE2 cells, β-catenin was located in cytoplasmic membranes and cytoplasm. Treatment with EGF (50 ng/mL) resulted in increased β-catenin nuclear staining, which was reversed by either gefitinib (1 μM) or LY294002 (15 μM).	31196210 23409107 23461856
Growth inhibition assay	GI50; PubMed: 23409107 PLoS One Dose-response of bladder cancer cell lines to EGFR inhibitor (gefitinib). The GI50 value was defined as the mean concentration of drug that generates 50% of growth inhibition as compared to controls.	23409107

In vivo

Gefitinib (100 mg/kg) improves the anti-tumor effect of radiotherapy in LoVo tumor xenografts. ^[3] Gefitinib treatment of nude mice bearing established human GEO colon cancer xenografts reveals a reversible dose-dependent inhibition of tumor growth because GEO tumors resumes the growth rate of controls at the end of the treatment. ^[4]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: NR6, NR6M and NR6W cells
Concentrations: 0-2 μM
Incubation Time: 72 hours
Method:
Exponentially growing cells including NR6, NR6M, NR6M and NR6W cells are seeded in sextuple in 96-well plates at a concentration of 2000 cells/well, allowed to adhere and subsequently washed in PBS and incubated overnight in medium containing 0.5% FCS. Cells are then treated with varying concentrations (0-2 μM) of Gefitinib or the solute control DMSO and EGF. The optimal EGF concentration for inducing proliferation of NR6wtEGFR and NR6W cells has previously been determined and hence NR6wtEGFR and NR6W cells are supplemented with 10 nM and 0.1 nM EGF, respectively. EGF is not added to NR6 and NR6M cells. After 72 hours the amount of cells are measured by performing a MTT proliferation assay.

(Only for Reference)

Animal Research:

^[3]

- Collapse

Animal Models: Female nude mice (cba nu/nu) aged 8–10 weeks are intra-dermal injected with LoVo cells.
Dosages: 100 mg/kg
Administration: Once daily by oral administration (0.1 mL/10 g body weight) for 14 days
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	89 mg/mL (199.14 mM)
	Ethanol	4 mg/mL (8.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Gefitinib (ZD1839) SDF

Molecular Weight	446.90
Formula	C₂₂H₂₄ClFN₄O₃
CAS No.	184475-35-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Iressa
Smiles	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03292133	Recruiting	Drug: EGF816\|Drug: Gefitinib	Lung Cancer	Massachusetts General Hospital\|Novartis	October 31 2017	Phase 2
NCT03122717	Active not recruiting	Drug: Gefitinib\|Drug: Osimertinib	Non-Small Cell Lung Cancer	Dana-Farber Cancer Institute\|AstraZeneca	May 9 2017	Phase 1\|Phase 2
NCT02932345	Completed	--	EGFR Mutation Positive Advanced Non-small-cell Lung Cancer	AstraZeneca	October 31 2016	--
NCT02824458	Recruiting	Drug: Apatinib\|Drug: Gefitinib\|Drug: Placebo	EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors	Sun Yat-sen University	June 2016	Phase 3
NCT02804776	Unknown status	Drug: Gefitinib	Non-small Cell Lung Cancer	National Cancer Centre Singapore	February 2015	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I try to dissolve Gefitinib (ZD1839) in 0.5% methylcellulose+0.2% Tween 80 for in vivo experiments. However, when I prepare the mixture, it forms precipitates. Exists another way to dissolve completely the compound?
Answer:
S1025 can be dissovled in both 5% DMSO+corn oil and 5% DMSO+30% PEG 300+5% Tween 80+ddH2O at 2.5 mg/ml clearly. It dissolves in DMSO not readily, please sonicate and warm it in water bath at about 45 degree, and dissolve it clearly first. Then add other solvent.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Pan EGFR Inhibitor

AZD8931 (Sapitinib) : Pan-ErbB inhibitor, EGFR/ErbB2/ErbB3, IC50=4 nM/3 nM/4 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib (OSI-774) ^New

Erlotinib (OSI-774, CP358774, NSC 718781, Tarceva) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib (GW-572016)

Lapatinib (GW-572016, GSK572016, GW2016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

Gefitinib (ZD1839)